皮膚科臨床アセット　7　皮膚科　膠原病診療のすべて

出版社： 中山書店
著者：
発行日： 2011-11-10
分野： 臨床医学：内科  >  皮膚科
ISBN： 9784521733449
シリーズ： 皮膚科臨床アセット
電子書籍版： 2011-11-10 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

15,400 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

15,400 円(税込)

購入する

商品紹介

全身性エリテマトーデス，全身性強皮症，皮膚筋炎を中心に，膠原病診療の知識を詳述。また各疾患の特徴的な皮膚症状をカラー写真でわかりやすく解説。さらに抗核抗体の読み方やそれぞれの膠原病で検出される自己抗体など，病態についての免疫学的な知識から，B細胞をターゲットにした最新の治療法まで網羅。他科を先導し膠原病診療を積極的に進める皮膚科医必携の一冊。

目次

  • 皮膚科臨床アセット　7　皮膚科　膠原病診療のすべて

    ―目次―

    I　抗核抗体
    II　Raynaud症状
    III　全身性エリテマトーデス
    IV　円板状エリテマトーデス
    V　亜急性皮膚エリテマトーデス
    VI　エリテマトーデス類縁疾患
    VII　全身性強皮症
    VIII　限局性強皮症
    IX　強皮症類縁疾患
    X　皮膚筋炎
    XI　Sjogren症候群
    XII　関節リウマチ
    XIII　混合性結合組織病
    XIV　オーバーラップ症候群
    XV　成人Still病
    XVI　ヒトアジュバント病
    XVII　抗リン脂質抗体症候群
    XVIII　Behcet病
    XIX　血球貪食症候群
    XX　膠原病の新規治療

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 抗核抗体

P.2 掲載の参考文献
1) 三森経世. 核抗原に対する自己抗体. 医学のあゆみ 2009 ; 230 : 698-703.
Medical*Online
2) 石原康. 自己抗体. 臨床病理 2005 ; 53 : 562-9.
 
3) Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003 ; 349 : 1526-33.
PubMed
4) Kuwana M, Okano Y, Pandey JP, et al. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody : analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 2005 ; 52 : 2425-32.
PubMed
5) Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002 ; 28 : 859-90.
PubMed
6) Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis : an association with malignancy. Rheumatology (Oxford) 2007 ; 46 : 25-8.
PubMed
7) Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006 ; 54 : 3682-9.
PubMed
8) Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005 ; 52 : 1571-6.
PubMed

II Raynaud 症状

P.10 掲載の参考文献
1) Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001 ; 357 : 2042-8.
PubMed
1) Herrick AL, Cutolo M. Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 2010 ; 62 : 2595-604.
PubMed
2) Suter LG, Murabito JM, Felson DT, et al. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum 2005 ; 52 : 1259-63.
PubMed
3) Hirschl M, Hirschl K, Lenz M, et al. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease. Arthritis Rheum 2006 ; 54 : 1974-81.
PubMed
4) Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology 2005 ; 44 : 587-96.
PubMed
5) Takehara K, Soma Y, Ishibashi Y. Early detection of scleroderma spectrum disorders in patients with Raynaud's phenomenon. Dermatologica 1991 ; 183 : 164-8.
PubMed
6) Sato S, Takehara K, Soma Y, et al. Diagnostic significance of nailfold bleeding in scleroderma spectrum disorders. J Am Acad Dermatol 1993 ; 28 : 198-203.
PubMed

III 全身性エリテマトーデス

P.16 掲載の参考文献
1) Cohen AS, Reynolds WE, Franklin EC, et al. Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 1971 ; 21 : 643-8.
 
2) Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982 ; 25 : 1271-7.
PubMed
3) Yokohari R, Tsunematsu T. Application, to Japanese patients, of the 1982 American Rheumatism Association revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1985 ; 28 : 693-8.
PubMed
4) Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986 ; 13 : 486-9.
PubMed
5) Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997 ; 40 : 1725.
PubMed
6) 吉田俊治. 膠原病の診断基準の進歩. 医学のあゆみ 2001 ; 199 : 321-5.
Medical*Online
7) 衛藤光. 全身性エリテマトーデス-分類基準に含まれる皮膚病変. 竹原和彦, ほか編新・膠原病. 東京 : 診断と治療社 ; 2002. pp66-71.
 
8) 橋本博史. 全身性エリテマトーデス (SLE) の診断プロトコル. メディカルテクノロジー 2000 ; 28 : 430-41.
 
9) 菊地弘敏, 広畑俊成. 膠原病の合併症とその対策 CNSループス. リウマチ科 2008 ; 39 : 125-31.
 
10) 岡寛. 膠原病に伴う血球貪食症候群. 竹原和彦, ほか編. 新・膠原病. 東京 : 診断と治療社 ; 2002. pp214-6.
 
11) 三森経世. 膠原病・リウマチ性疾患における自己抗体. 狩野庄吾, ほか編. アレルギー・リウマチ・膠原病の最新医療. 東京 : 先端医療技術研究所 ; 2003. pp242-7.
 
12) 近藤啓文, 石川章. 混合性結合組織病. 狩野庄吾, ほか編. アレルギー・リウマチ・膠原病の最新医療. 東京 : 先端医療技術研究所 ; 2003. pp309-13.
 
13) 橋本博史. 全身性エリテマトーデスとその類縁疾患. 綜合臨牀 2002 ; 51 (増刊号) 1782-6.
 
P.23 掲載の参考文献
1) Lee YH, Ota F, Kim-Howard X, et al. APRIL polymorphism and systemic lupus erythematosus (SLE) susceptibility. Rheumatology (Oxford) 2007 ; 46 : 1274-6.
PubMed
1) Gerl V, Lischka A, Panne D, et al. Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function. Ann Rheum Dis 2010 ; 69 : 1370-7.
PubMed
2) Jacob CO, Zhu J, Armstrong DL, et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA 2009 ; 106 : 6256-61.
PubMed
3) Barreto M, Ferreira RC, Lourengo L, et al. Low frequency of CD4+ CD25+ Treg in SLE patients :a h eritable trait associated with CTLA4 and TGFbeta gene variants. BMC Immunol 2009 ; 10 : 5.
 
4) Bynote KK, Hackenberg JM, Korach KS, et al. Estrogen receptor-a deficiency attenuates autoimmune disease in (NZB x NZW) F1 mice. Genes Immun 2008 ; 9 137-52.
PubMed
5) Foitzik K, Langan EA, Paus R. Prolactin and the skin : a dermatological perspective on an ancient pleiotropic peptide hormone. J Invest Dermatol 2009 ; 129 : 1071-87.
 
6) Getts MT, Miller SD. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders : triggering of autoimmune diseases by infections. Clin Exp Immunol 2010 ; 160 : 15-21.
PubMed
7) Toussirot E, Roudier J. Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol 2008 ; 22 : 883-96.
PubMed
8) Masutani K, Akahoshi M, Tsuruya K, et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001 ; 44 : 2097-106.
PubMed
9) Shah K, Lee WW, Lee SH, et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther 2010 ; 12 : R53.
PubMed
10) Huang X, Hua J, Shen N, et al. Dysregulated expression of interleukin-23 and interleukin-12 subunits in systemic lupus erythematosus patients. Mod Rheumatol 2007 ; 17 : 220-3.
 
11) Tokano Y, Morimoto S, Kaneko H, et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE) -relation to Th1- and Th2-derived cytokines. Clin Exp Immunol 1999 ; 116 : 169-73.
PubMed
12) Anolik JH. B cell biology and dysfunction in SLE. Bull NYU Hosp Jt Dis 2007 ; 65 : 182-6.
PubMed
13) Fukuyama H, Nimmerjahn F, Ravetch JV. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol 2005 ; 6 : 99-106.
PubMed
14) Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002 ; 3 : 822-9.
PubMed
15) Farkas L, Beiske K, Lund-Johansen F, et al. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001 ; 159 : 237-43.
PubMed
16) Boule MW, Broughton C, Mackay F, et al. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004 ; 199 : 1631-40.
PubMed
17) Ebert LM, Horn MP, Lang AB, et al. B cells alter the phenotype and function of follicular-homing CXCR5+ T cells. Eur J Immunol 2004 ; 34 : 3562-71.
PubMed
18) Doreau A, Belot A, Bastid J, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009 ; 10 : 778-85.
PubMed
19) Bryant VL, Ma CS, Avery DT, et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells : predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J Immunol 2007 ; 179 : 8180-90.
 
20) Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003 ; 197 : 711-23.
 
21) Yoshimoto K, Takahashi Y, Ogasawara M, et al. Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy. Int Immunol 2006 ; 18 : 1189-96.
 
22) Baima B, Sticherling M. Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol 2001 ; 144 : 958-66.
PubMed
P.30 掲載の参考文献
1) 植木宏明. 概念とその変遷-疫学・病因論・病型分類を含む. 今村貞夫, ほか編. エリテマトーデスの臨床. 皮膚科Mook 7. 東京 : 金原出版 ; 1986. pp1-11.
 
2) 土田哲也, 盛岡奈緒子, 上田純嗣, ほか. エリテマトーデスの診断名と皮疹名. 皮膚臨床 1990 ; 32 : 1139-49.
 
3) Watanabe T, Tsuchida T. Classification of lupus erythematosus based upon cutaneous manifestation. Dermatology 1995 ; 190 : 277-83.
PubMed
P.34 掲載の参考文献
1) 土田哲也, 盛岡奈緒子, 上田純嗣, ほか. エリテマトーデスの診断名と皮疹名. 皮膚臨床 1990 ; 32 : 1139-49.
 
2) Watanabe T, Tsuchida T. Classification of lupus erythematosus based upon cutaneous manifestation. Dermatology 1995 ; 190 : 277-83.
PubMed
P.40 掲載の参考文献
1) Petri MA. Systemic lupus erythematosus : clinical aspects. In : Koopman WJ, et al, editors. Arthritis and Allied Conditions. 15th edition. Philadelphia : Lippincott Williams & Wilkins ; 2004. pp1480-1.
 
2) 長田道夫, 槙野博史, 秋草文四郎, ほか. ループス腎炎病理診断の新しい分類 : ISN/RPS 2003年改訂分類の要点と診断マニュアル. 日腎会誌 2004 ; 46 : 383-95.
 
3) ACR ad hoc committee on neuropsychiatric lupus nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999 ; 42 : 599-608.
 
4) 塩沢俊一. 全身性エリテマトーデス. 塩沢俊一. 膠原病学. 東京 : 丸善 ; 2003. pp309-49.
 
P.44 掲載の参考文献
1) 窪田哲朗. 免疫学的検査 自己免疫関連検査 抗DNA抗体. Medicina 2010 ; 47 : 438-9.
 
2) 上阪等. 免疫学的検査 自己免疫関連検査 抗Sm抗体. Medicina 2010 ; 47 : 442-3.
 
3) 石井亘, 真村瑞子, 住田孝之. 抗RNP抗体, 抗Sm抗体. 中井利昭, 編. 検査値のみかた. 改訂3版. 東京 : 中外医学社 ; 2006.
 
4) 竹内健, 松平蘭, 松下雅和. 臨床検査病態へのアプローチ 全身性エリテマトーデス. 医学検査 2002 ; 51 : 1256-64.
 
5) 佐々木毅. 免疫学的検査 自己抗体 抗DNA抗体. 日本臨牀 2010 ; 68 : 517-21.
 
P.51 掲載の参考文献
1) Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992 ; 35 : 630-40.
 
2) Liang MH, Socher SA, Larson MG, et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989 ; 32 : 1107-18.
PubMed
3) Yee CS, Farewell V, Isenberg DA, et al. Revised British Isles Lupus Assessment Group 2004 index : a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 2006 ; 54 : 3300-5.
PubMed
4) 横張龍一. SLE活動性判定基準. 厚生省特定疾患自己免疫疾患調査研究班 (恒松徳五郎班長), 昭和60年度研究業績集. 1986. pp50-7.
 
5) Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index) : an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005 ; 125 : 889-94.
PubMed
6) 衛藤光, 新井春枝, 浅井俊弥, ほか. SLEの皮膚症状の統計. 皮膚病診療 1996 ; 18 : 543-7.
 
7) 新井春枝, 衛藤光, 西山茂夫. 皮膚病変からみたSLEの予後. 皮膚臨床 1980 ; 22 : 651-9.
 
8) Yasue T. Livedoid vasculitis and central nervous system involvement in systemic lupus erythematosus. Arch Dermatol 1986 ; 122 : 66-70.
PubMed
P.56 掲載の参考文献
1) 橋本博史. SLEの病型分類とそれに対応する治療法. 医学のあゆみ 1991 ; 158 : 69-73.
Medical*Online
2) 市川陽一, 恒松徳五郎, 横張龍一, ほか. SLEの死因に関する多施設共同研究第二報 : 罹患期間および年代による変遷. 厚生省特定疾患自己免疫疾患調査研究班 (恒松徳五郎班長), 昭和59年度研究業績集. 1985. pp37-41.
 
3) 市川陽一. 膠原病の予後. 綜合臨牀 1987 ; 36 : 1801-6.
 
4) 石川治, 田村敦志, 宮地良樹. 当科における過去15年間 (1979-1994) の全身性エリテマトーデス死亡12例の死因について. 皮膚臨床 1995 ; 1685-8.
 
P.60 掲載の参考文献
1) Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999 ; 169 : 107-21.
PubMed
2) Koshy M, Berger D, Crow MK, et al. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996 ; 98 : 826-37.
PubMed
3) Mitchell JP, Enyedy EJ, Nambiar MP, et al. Engagement of complement receptor 2 on the surface of B cells from patients with systemic lupus erythematosus contributes to the increased responsiveness to antigen stimulation. Lupus 2002 ; 11 : 299-303.
 
4) Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002 ; 46 : 2673-77.
PubMed
5) Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010 ; 6 : 326-37.
PubMed
P.63 掲載の参考文献
1) 土屋尚之. 膠原病の疾患感受性遺伝子解析. 臨牀と研究 2010 ; 87 : 1184-9.
Medical*Online
1) Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008 ; 358 : 900-9.
PubMed
2) 土屋尚之. 膠原病のゲノム解析. カレントテラピー 2010 ; 28 : 884-90.
 
2) International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), Harley JB, Alarcon-Riquelme ME, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008 ; 40 : 204-10.
 
3) Gateva V, Sandling JK, Hom G, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009 ; 41 : 1228-33.
 
3) 土屋尚之, 伊東郁恵, 川崎 綾. IRF5, STAT4, BLKと全身性エリテマトーデスをはじめとする膠原病との関連. 日本臨床免疫学会会誌 2010 ; 33 : 57-65.
Medical*Online
4) Han JW, Zheng HF, Cui Y, et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 2009 ; 41 : 1234-7.
 
5) Yang W, Shen N, Ye D-Q, et al. Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet 2010 ; 6 : e1000841.
PubMed
6) Tsuchiya N, Ohashi J, Tokunaga K. Variations in immune response genes and their associations with multifactorial immune disorders. Immunol Rev 2002 ; 190 : 169-81.
PubMed
7) Ito I, Kawasaki A, Ito S, et al. Replication of the association between C8orf13-BLK region and systemic lupus erythematosus in a Japanese population. Arthritis Rheum 2009 ; 60 : 553-8.
 
8) Kyogoku C, Dijstelbloem HM, Tsuchiya N, et al. Fcγ receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus : contribution of FCGR2B to genetic susceptibility. Arthritis Rheum 2002 ; 46 : 1242-54.
 
9) Kawasaki A, Ito I, Hikami K, et al. Role of STAT4 polymorphisms in systemic lupus erythematosus in a Japanese population : a case-control association study of the STAT1-STAT4 region. Arthritis Res Ther 2008 ; 10 : R113.
 
10) Kawasaki A, Tsuchiya N, Ohashi J, et al. Role of APRIL (TNFSF13) polymorphisms in the susceptibility to systemic lupus erythematosus in Japanese. Rheumatology 2007 ; 46 : 776-82.
PubMed
11) Kawasaki A, Ito I, Ito S, et al. Association of TNFAIP3 polymorphism with susceptibility to systemic lupus erythematosus in a Japanese population. J Biomed Biotechnol 2010 ; 2010 : 207578.
 
12) Kawasaki A, Kyogoku C, Ohashi J, et al. Association of IRF5 polymorphisms with systemic lupus erythematosus in a Japanese population : support for a crucial role of intron 1 polymorphisms. Arthritis Rheum 2008 ; 58 : 826-34.
 
13) Kawasaki A, Ito S, Furukawa H, et al. Association of TNFAIP3 interacting protein 1, TNIP1 with systemic lupus erythematosus in a Japanese population : a casecontrol association study. Arthritis Res Ther 2010 ; 12 : R174.
 
14) Pickering MC, Botto M, Taylor PR, et al. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000 ; 76 : 227-324.
PubMed
15) Yang Y, Chung EK, Wu YL, et al. Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE) : low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 2007 ; 80 : 1037-54.
PubMed
16) Dijstelbloem HM, van de Winkel JG, Kallenberg CG. Inflammation in autoimmunity : receptors for IgG revisited. Trends Immunol 2001 ; 22 : 510-6.
PubMed
17) Fanciulli M, Norsworthy PJ, Petretto E, et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet 2007 ; 39 : 721-3.
 
18) Niederer HA, Willcocks LC, Rayner TF, et al. Copy number, linkage disequilibrium and disease association in the FCGR locus. Hum Mol Genet 2010 ; 19 : 3282-94.
 
19) Tsuchiya N, Honda Z, Tokunaga K. Role of B cell inhibitory receptor polymorphisms for systemic lupus erythematosus : a negative times a negative makes a positive. J Hum Genet 2006 ; 51 : 741-50.
PubMed
20) Kono H, Kyogoku C, Suzuki T, et al. FcγRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet 2005 ; 14 : 2881-92.
 
21) Floto RA, Clatworthy MR, Heilbronn KR, et al. Loss of function of a lupus-associated FcγRIIb polymorphism through exclusion from lipid rafts. Nat Med 2005 ; 11 : 1056-8.
 
22) Ito I, Kawaguchi K, Kawasaki A, et al. Association of the FAM167A-BLK region with systemic sclerosis. Arthritis Rheum 2010 ; 62 : 890-5.
 
23) Ito I, Kawasaki A, Ito S, et al. Replication of association between FAM167A (C8orf13) -BLK region and rheumatoid arthritis in a Japanese population. Ann Rheum Dis 2010 ; 69 : 936-7.
 
24) Kyogoku C, Tsuchiya N. A compass that points to lupus : genetic studies on type I interferon pathway. Genes Immun 2007 ; 8 : 445-55.
PubMed
25) Ito I, Kawaguchi Y, Kawasaki A, et al. Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum 2009 ; 60 : 1845-50.
 
26) Shen N, Fu Q, Deng Y, et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci U S A 2010 ; 107 : 15838-43.
PubMed
27) Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007 ; 357 : 977-86.
PubMed
28) Tsuchiya N, Kawasaki A, Hasegawa M, et al. Association of STAT4 polymorphism with systemic sclerosis in a Japanese population. Ann Rheum Dis 2009 ; 68 : 1375-6.
 
P.68 掲載の参考文献
1) Furukawa F. Photosensitivity in cutaneous lupus erythematosus : lessons from mice and men. J Dermatol Sci 2003 ; 33 : 81-9.
 
2) Xue D, Shi H, Smith JD, et al. A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. Proc Natl Acad Sci U S A 2003 ; 100 : 7503-8.
 
3) Gerl V, Hostmann B, Johnen C, et al. The intracellular 52-kd Ro/SSA autoantigen in keratinocytes is up-regulated by tumor necrosis factor alpha via tumor necrosis factor receptor I. Arthritis Rheum 2005 ; 52 : 531-8.
PubMed
4) Reed JH, Jackson MW, Gordon TP. A B cell apotope of Ro 60 in systemic lupus erythematosus. Arthritis Rheum 2008 ; 58 : 1125-9.
 
5) Reed JH, Giannakopoulos B, Jackson MW, et al. Ro 60 functions as a receptor for beta (2) -glycoprotein I on apoptotic cells. Arthritis Rheum 2009 ; 60 : 860-9.
PubMed
P.70 掲載の参考文献
1) Huang YP, Miescher PA, Zubler RH. The interleukin-2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells. J Immunol 1986 ; 137 : 3515-20.
PubMed
2) Amano K, Takeuchi T, Abe T, et al. Umbalanced tyrosine phosphorylation in signal transduction molecules in SLE T cells. Arthritis Rheum 1996 ; 39 : S118.
 
3) Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 1991 ; 64 : 891-901.
 
4) 竹内勤. SLEのT細胞シグナル伝達異常. 医学のあゆみ 1996 ; 176 : 335.
Medical*Online
5) Takeuchi T, Tsuzaka K, Pang M, et al. TCRζ chain lacking exon 7 in two patients with systemic lupus erythematosus. Int Immunol 1998 ; 10 : 911-21.
 
6) Pang M, Setoyama Y, Tsuzaka K, et al. Defective expression and tyrosine phosphorylation of the T cell receptor ζ chain in peripheral blood T cells from systemic lupus erythematosus patients. Clin Exp Immunol 2002 ; 129 : 160-8.
 
7) Tsuzaka K, Takeuchi T, Onoda N, et al. Mutations in T cell receptor ζ chain mRNA of peripheral T cells from systemic lupus erythematosus. J Autoimmunity 1998 ; 11 : 381-5.
 
8) Tsuzaka K, Onoda N, Yoshimoto K, et al. T-cell receptor ζ mRNA with alternatively spliced 3' untranslated region is generated predominantly in the peripheral blood T cells of systemic lupus erythematosus patients. Mod Rheumatol 2002 ; 12 : 167-73.
 
9) Tsuzaka K, Fukuhara I, Setoyama Y, et al. TCRζ mRNA with an alternatively spliced 3' untranslated region detected in SLE patients leads to the downregulation of TCRζ and TCR/CD3 complex. J Immunol 2003 ; 171 : 2496-503.
 
10) Tsuzaka K, Setoyama Y, Yoshimoto K, et al. A splice variant of the TCR ζ mRNA lacking exon 7 leads to the down-regulation of TCR ζ, the TCR/CD3 complex, and IL-2 production in SLE T cells. J Immunol 2005 ; 174 : 3518-25.
 
11) Tsuzaka K, Itami Y, Kumazawa C, et al. Conservative sequences in 3' UTR of TCRζ mRNA regulate TCRζ in SLE T cells. Biochem Biophys Res Commun 2008 ; 367 : 311-7.
 
P.73 掲載の参考文献
1) Ghoreishi M, Dutz JP. Murine models of cutaneous involvement in lupus erythematosus. Autoimmun Rev 2009 ; 8 : 484-7.
PubMed
2) Furukawa F. Photosensitivity in cutaneous lupus erythematosus : lessons from mice and men. J Dermatol Sci 2003 ; 33 : 81-9.
 
3) Xue D, Shi H, Smith JD, et al. A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. Proc Natl Acad Sci U S A 2003 ; 100 : 7503-8.
 
4) Yoshimasu T, Nishide T, Seo N, et al. Susceptibility of T cell receptor-alpha chain knock-out mice to ultraviolet B light and fluorouracil : a novel model for drug-induced cutaneous lupus erythematosus. Clin Exp Immunol 2004 ; 136 : 245-54.
PubMed

IV 円板状エリテマトーデス

P.78 掲載の参考文献
1) 土田哲也. 皮膚エリテマトーデス. 玉置邦彦, ほか編. 最新皮膚科学大系 9. 膠原病 非感染性肉芽腫. 東京 : 中山書店 ; 2002. pp61-9.
 
2) 盛岡奈緒子, 土田哲也, 上田純嗣, ほか. 男性全身性エリテマトーデスの臨床像について-当科22例の総括. 日皮会誌 1990 ; 100 : 761-72.
 
3) 土田哲也, 盛岡奈緒子, 上田純嗣, ほか. エリテマトーデスの診断名と皮疹名. 皮膚臨床 1990 ; 32 : 1139-49.
 
4) 安部正敏, 石川治. 皮膚限局型エリテマトーデス. MB Derma 2005 ; 99 : 31-8.
 
5) 安部正敏, 石川治. 円板状エリテマトーデスのdiaphenyl-sulfone (DDS) 療法. 臨皮 1999 ; 53 : 127-32.
 
6) 土田哲也. 慢性円板状エリテマトーデスの治療. 臨皮 1997 ; 51 : 128-33.
 

V 亜急性皮膚エリテマトーデス

P.82 掲載の参考文献
1) Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus : a cutaneous marker for distinct lupus erythematosus subset. Arch Dermatol 1979 ; 115 : 1409-15.
PubMed
2) Nishikawa T, Provost TT. Differences in clinical, serologic, and immunogenetic features of white versus oriental anti SS-A/Ro-positive patients. J Am Acad Dermatol 1991 ; 25 : 563-4.
 
3) 衛藤光, 上村仁夫, 寺本範子, ほか. 亜急性皮膚エリテマトーデス. 皮膚病診療 1987 ; 9 : 631-4.
 
4) Lehmann P, Holzle E, Kind P, et al. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol 1990 ; 22 : 181-7.
PubMed
5) Bangert JL, Freeman R, Sontheimer RD, et al. Subacute cutaneous lupus erythematosus and discoid lupus erythematosus : comparative histopathologic findings. Arch Dermatol 1984 ; 120 : 332-7.
PubMed
6) Werth VP, Zhang W, Dortzbach K, et al. Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. J Invest Dermatol 2000 ; 115 : 726-30.
PubMed
7) Katayama I, Teramoto N, Arai H, et al. Annular erythema : a comparative study of Sjogren syndrome with subacute cutaneous lupus erythematosus. Int J Dermatol 1991 ; 30 : 635-9.
PubMed

VI エリテマトーデス類縁疾患

P.86 掲載の参考文献
1) 城所朋子, 溝口昌子. 深在性ループスエリテマトーデス. 皮膚病診療 1997 ; 19 : 543-6.
 
2) Tuffanelli DL. Lupus erythematosus panniculitis (profundus). Arch Dermatol 1971 ; 103 : 231-42.
PubMed
3) Irgang S. Apropos du lupus erythemateux profond. Archives of Dermatology and Syphilology 1940 ; 42 : 97-108.
 
4) 衛藤光. 皮膚ループスの病型分類と考え方. 日皮会誌 2008 ; 118 : 2568-71.
 
5) 土田哲也, 盛岡奈緒子, 上田純嗣, ほか. エリテマトーデス (LE) の診断名と皮疹名. 皮膚臨床 1990 ; 32 : 1139-49.
 
6) 新井春枝, 百瀬葉子, 新井達, ほか. 深在性エリテマトーデス. 皮膚病診療 2007 ; 29 : 1010-7.
 
7) 浅田秀夫. 深在性エリテマトーデス (LEP). 瀧川雅浩, ほか編. 皮膚疾患最新の治療 2007-2008. 東京 : 南江堂 ; 2006. p75.
 
8) 松田聡子, 橋本夏, 松本聡子, ほか. 報告例からみた深在性エリテマトーデス病型分類と治療法の検討. 臨皮 2005 ; 59 : 1255-60.
 
9) Espirito Santo J, Gomes MF, Gomes MJ, et al. Intravenous immunoglobulin in lupus panniculitis. Clin Rev Allergy Immunol 2010 ; 38 : 307-18.
PubMed
10) 吉村浩太郎. 陥凹の治療 自己脂肪注入, 幹細胞注入について. MB Derma 2010 ; 168 : 21-8.
Medical*Online
P.89 掲載の参考文献
1) Gold SC. An unusual papular eruption associated with lupus erythematosus. Br J Dermatol 1954 ; 66 : 429-33.
PubMed
2) 長島正治, 古川徹, 小林勝, ほか. 結節性皮膚ループスムチン症-結節状ムチン沈着を示した男子SLEの3例. 皮膚臨床 1985 ; 27 : 621-7.
 
3) Rongioletti F, Rebora A. The new cutaneous mucinoses : a review with an up-todate classification of cutaneous mucinoses. J Am Acad Dermatol 1991 ; 24 : 265-70.
 
4) Kobayashi T, Shimizu H, Shimizu S, et al. Plaquelike cutaneous lupus mucinosis. Arch Dermatol 1993 ; 129 : 383-4.
PubMed
5) 薄木晶子, 山田陽三, 堀川達弥, ほか. 結節性ループスムチン症の1例. 皮膚臨床 2003 ; 45 : 457-60.
 
6) Kanda N, Tsuchida T, Watanabe T, et al. Clinical features of systemic lupus erythematosus in men. Characteristics of the cutaneous manifestations. Dermatology 1996 ; 193 : 6-10.
PubMed
7) Kanda N, Tsuchida T, Watanabe T, et al. Cutaneous lupus mucinosis : a review of our cases and the possible pathogenesis. J Cutan Pathol 1997 ; 24 : 553-8.
PubMed
8) Egawa H, Abe-Matsuura Y, Tada J, et al. Nodular cutaneous lupus mucinosis associated with atrophie blanche-like lesions in a patient with systemic lupus erythematosus. J Dermatol 1994 ; 21 : 674-9.
 
9) 田中千洋, 白崎文朗, 平野貴士, ほか. 組織学的にLeukocytoclastic vasculitisを認めた結節性皮膚ループスムチン症の1例. 皮膚臨床 2003 ; 45 : 771-4.
 
10) 神田奈緒子, 渡邊孝宏. エリテマトーデスの特殊な皮疹. MB Derma 1997 ; 5 : 55-62.
 
11) Kuhn A, Richter-Hintz D, Oslislo C, et al. Lupus erythematosus tumidus-a neglected subset of cutaneous lupus erythematosus : report of 40 cases. Arch Dermatol 2000 ; 136 : 1033-41.
PubMed
12) 松本佳子, 村上信司, 橋本公二. Lupus erythematosus tumidus. 皮膚病診療 2004 ; 26 : 63-6.
 
13) 松本晴子, 夏秋優, 小倉千香, ほか. 結節性皮膚ループスムチン症の1例. 皮膚の科学 2004 ; 3 : 28-33.
 
14) 村上かおり, 鈴木寛丈, 工藤里香, ほか. 結節性皮膚ループスムチン症の1例. 皮膚 2000 ; 2 : 167-74.
 
15) 木村恭一, 原郁夫. 結節状ムチン沈着を示したSLE. 皮膚臨床 1987 ; 29 : 216-7.
 
16) Pandya AG, Sontheimer RD, Cockerell CJ, et al. Papulonodular mucinosis associated with systemic lupus erythematosus : possible mechanisms of increased glycosaminoglycan accumulation. J Am Acad Dermatol 1995 ; 32 (2 Pt 1) : 199-205.
 
17) Sampson PM, Rochester CL, Freundlich B, et al. Cytokine regulation of human lung fibroblast hyaluronan (hyaluronic acid) production : evidence for cytokineregulated hyaluronan (hyaluronic acid) degradation and human lung fibroblastderived hyaluronidase. J Clin Invest 1992 ; 90 : 1492-503.
PubMed
18) Terry DE, Clark AF. Glycosaminoglycans in the three lobes of the rat prostate following castration and testosterone treatment. Biochem Cell Biol 1996 ; 74 : 653-8.
PubMed
19) Ji H, Dailey TL, Long V, et al. Androgen-regulated cervical ripening : a structural, biomechanical, and molecular analysis. Am J Obstet Gynecol 2008 ; 198 : 543.e1-9.
 
20) de Deus JM, Girao MJ, Sartori MG, et al. Glycosaminoglycan profile in bladder and urethra of castrated rats treated with estrogen, progestogen, and raloxifene. Am J Obstet Gynecol 2003 ; 189 : 1654-9.
PubMed
21) Straach KJ, Shelton JM, Richardson JA, et al. Regulation of hyaluronan expression during cervical ripening. Glycobiology 2005 ; 15 : 55-65.
PubMed
22) Pugashetti R, Zedek DC, Seiverling EV, et al. Dermal mucinosis as a sign of venous insufficiency. J Cutan Pathol 2010 ; 37 : 292-6.
PubMed
23) 寺本範子, 衛藤光, 上村仁夫, ほか. 結節性ムチン沈着症を認めた全身性エリテマトーデス. 皮膚臨床 1988 ; 30 : 1433-7.
 
24) Mio K, Carrette O, Maibach HI, et al. Evidence that the serum inhibitor of hyaluronidase may be a member of the inter-alpha-inhibitor family. J Biol Chem 2000 ; 275 : 32413-21.
PubMed
25) 辰野優子, 橋爪鈴男, 小原理, ほか. Nodular cutaneous lupus mucinosis様病変と脂肪織炎を認めた皮膚筋炎の1例. 日皮会誌 1997 ; 107 : 449-56.
 
26) 澄川雅子. Papulonocular mucinosis associated with Sjogren's syndrome. 皮膚科紀要 1998 ; 93 : 663.
 
27) 庄田裕紀子. Subclinical Sjogren's syndromeを合併した結節性皮膚ループスムチン症の1例. 日皮会誌 1995 ; 105 : 399.
 
28) Van Zander J, Shaw JC. Papular and nodular mucinosis as a presenting sign of progressive systemic sclerosis. J Am Acad Dermatol 2002 ; 46 : 304-6.
PubMed
P.94 掲載の参考文献
1) 臼田俊和, 長嶋正實. 先天性完全房室ブロックとSjogren症候群. 皮膚病診療 1993 ; 15 : 69-72.
 
2) 衛藤光. 新生児エリテマトーデス. 玉置邦彦, ほか編. 最新皮膚科学大系 9. 膠原病 非感染性肉芽腫. 東京 : 中山書店 ; 2002. pp72-4.
 
3) 村島温子. 母体の抗SS-A抗体と新生児ループス発症との関連について. 第18回自己抗体と自己免疫シンポジウム. 東京. 2011年2月5日.
 
4) Llanos C, Izmirly P, Katholi M, et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum 2009 ; 60 : 3091-7.
PubMed
5) 新田悠紀子, 大野稔之, 嘉陽織江, ほか. シェーグレン症候群 (SjS) の家族例. 日皮会誌 2010 ; 120 : 1647-52.
 
6) Strandberg L, Salomonsson S, Bremme K, et al. Ro52, Ro60 and La IgG autoantibody levels and Ro52 IgG subclass profiles longitudinally throughout pregnancy in congenital heart block risk pregnancies. Lupus 2006 ; 15 : 346-53.
PubMed
7) 加藤豊章, 浅野善英, 柿沼誉, ほか. 新生児エリテマトーデスの1例. 皮膚臨床 2010 ; 52 : 1205-8.
 
8) 平野直子, 新田悠紀子, 小池文美香, ほか. 新生児エリテマトーデスの1例. 皮膚臨床 2006 ; 48 : 625-8.
 
9) 小中理会, 新井達, 衛藤光. 自然消褪する皮膚病 (臨床例) 3. 新生児エリテマトーデス. 皮膚病診療 2003 ; 25 : 743-6.
 
10) 臼田俊和. Sjogren症候群における環状紅斑. Visual Dermatology 2009 ; 8 : 1056-8.
 
P.98 掲載の参考文献
1) Camsia C, Sharma HM. Vesiculobullous systemic lupus erythematosus. J Am Acad Dermatol 1983 ; 9 : 924-33.
 
2) Yell JA, Allen J, Wojnarowska F, et al. Bullous systemic lupus erythematosus : revised criteria for diagnosis. Br J Dermatol 1995 ; 132 : 921-8.
PubMed
3) Ishikawa O, Zaw KK, Miyachi Y, et al. The presence of anti-basement membrane zone antibodies in the sera of patients with non-bullous lupus erythematosus. Br J Dermatol 1997 ; 136 : 222-6.
PubMed
4) Gammon WR, Woodley DT, Dole KC, et al. Evidence that anti-basement membrane zone antibodies in bullous eruption of systemic lupus erythematosus recognize epidermolysis bullosa acquisita autoantigen. J Clin Invest 1985 ; 84 : 472-6.
 
5) Alahlafi AM, Wordsworth P, Wojnarowska F, et al. The lupus band : do the autoantibodies target collagen VII? Br J Dermatol 2004 ; 150 : 504-10.
PubMed
P.101 掲載の参考文献
1) Hutchinson J. Harvean lectures on lupus. Br Med J 1888 ; 1 : 58-63.
PubMed
2) 衛藤光, 新井春枝, 浅井俊弥, ほか. SLEの皮膚症状の統計. 皮膚病診療 1996 ; 18 : 543-7.
 
3) 土田哲也, 盛岡奈緒子, 上田純嗣, ほか. エリテマトーデスの診断名と皮疹名. 皮膚臨床 1990 ; 32 : 1139-49.
 
P.104 掲載の参考文献
1) 三森経世. 薬剤誘発性ループス. 竹原和彦, ほか編. 膠原病-診断と治療の最新ポイント. 東京 : 診断と治療社 ; 1997. pp156-9.
 
2) Antonov D, Kazandjieva J, Etugov D, et al. Drug-induced lupus erythematosus. Clin Dermatol 2004 ; 22 : 157-66.
PubMed
3) Katz U, Zandman-Goddard G. Drug-induced lupus : an update. Autoimmun Rev 2010 ; 10 : 46-50.
PubMed
4) Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009 ; 48 : 716-20.
PubMed
5) Mor A, Bingham C, 3rd, Barisoni L, et al. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 2005 ; 32 : 740-3.
PubMed
6) Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008 ; 37 : 381-7.
PubMed
7) Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies : analysis of 233 cases. Medicine (Baltimore) 2007 ; 86 : 242-51.
PubMed
8) Rubin RL, Waga S. Antihistone antibodies in systemic lupus erythematosus. J Rheumatol 1987 ; 14 (Suppl 13) : 118-26.
 
P.107 掲載の参考文献
1) Obermoser G, Sontheimer RD, Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus 2010 ; 19 : 1050-70.
 
1) Gougerot H, Bournier R. Lupus erythemateux "tumidus". Bull Soc Fr Dermatol Syphiligr 1930 ; 37 : 1291-2.
 
2) Kuhn A, Richter-Hintz D, Oslislo C, et al. Lupus erythematosus tumidus-a neglected subset of cutaneous lupus erythematosus : report of 40 cases. Arch Dermatol 2000 ; 136 : 1033-41.
PubMed
3) Choonhakarn C, Poonsriaram A, Chaivoramukul J. Lupus erythematosus tumidus. Int J Dermatol 2004 ; 43 : 815-8.
PubMed
4) Kuhn A, Sonntag M, Richter-Hintz D, et al. Phototesting in lupus erythematosus tumidus-review of 60 patients. Photochem Photobiol 2001 ; 73 : 532-6.
PubMed
5) Kuhn A, Sonntag M, Ruzicka T, et al. Histopathologic findings in lupus erythematosus tumidus : review of 80 patients. J Am Acad Dermatol 2003 ; 48 : 901-8.
PubMed
6) Alexiades-Armenakas MR, Baldassano M, Bince B, et al. Tumid lupus erythematosus : criteria for classification with immunohistochemical analysis. Arthritis Rheum 2003 ; 49 : 494-500.
PubMed
7) Cozzani E, Christana K, Rongioletti F, et al. Lupus erythematosus tumidus : clinical, histopathological and serological aspects and therapy response of 21 patients. Eur J Dermatol 2010 ; 20 : 797-801.
PubMed

VII 全身性強皮症

P.112 掲載の参考文献
1) Henault J, Tremblay M, Clement I, et al. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 2004 ; 50 : 3265-74.
 
2) Robitaille G, Henault J, Christin MS, et al. The nuclear autoantigen CENP-B displays cytokine-like activities toward vascular smooth muscle cells. Arthritis Rheum 2007 ; 56 : 3814-26.
PubMed
3) Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006 ; 354 : 2667-76.
 
4) Allanore Y, Dieude P, Boileau C. Updating the genetics of systemic sclerosis. Curr Opin Rheumatol 2010 ; 22 : 665-70.
PubMed
5) Radstake TR, Gorlova O, Rueda B, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010 ; 42 : 426-9.
PubMed
6) Fujimoto M, Sato S. B cell signaling and autoimmune diseases : CD19/CD22 loop as a B cell signaling device to regulate the balance of autoimmunity. J Dermatol Sci 2007 ; 46 : 1-9.
 
P.115 掲載の参考文献
1) Ihn H. Autocrine TGF-β signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 2008 ; 49 : 103-13.
 
2) Jinnin M. Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol 2010 ; 37 : 11-25.
PubMed
3) Asano Y. Future treatments in systemic sclerosis. J Dermatol 2010 ; 37 : 54-70.
PubMed
P.118 掲載の参考文献
1) LeRoy EC. Systemic sclerosis : a vascular perspective. Rheum Dis Clin North Am 1996 ; 22 : 675.
PubMed
1) Gabrielli A, Avvedimento EV, Krieg T. Mechanisms of disease : scleroderma. N Engl J Med 2009 ; 360 : 1989-2003.
 
2) Kahaleh B. Vascular disease in scleroderma : mechanisms of vascular injury. Rheum Dis Clin North Am 2008 ; 34 : 57-71.
PubMed
3) Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 2010 ; 6 : 453-60.
PubMed
4) Lunardi C, Bason C, Navone R, et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000 ; 6 : 1183-6.
PubMed
5) Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis : increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002 ; 4 : R11.
PubMed
6) Giusti B, Fibbi G, Margheri F, et al. A model of anti-angiogenesis : differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther 2006 ; 8 : R115.
 
7) Kuwana M, Okazaki Y, Yasuoka H, et al. Defective vasculogenesis in systemic sclerosis. Lancet 2004 ; 364 : 603-10.
PubMed
P.121 掲載の参考文献
1) American Rheumatism Association. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980 ; 23 : 581-90.
PubMed
2) 竹原和彦, 佐藤伸一, 古江増隆. 全身性強皮症・診療ガイドライン. 日皮会誌 2007 ; 117 : 2431-43.
 
3) Maricq HR, LeRoy EC, D'Angelo WA, et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 1980 ; 23 : 183-9.
PubMed
4) Ihn H, Sato S, Tamaki T, et al. Clinical evaluation of scleroderma spectrum disorders using a points system. Arch Dermatol Res 1992 ; 284 : 391-5.
PubMed
5) Haustein UF. Scleroderma and pseudo-scleroderma : uncommon presentations. Clin Dermatol 2005 ; 23 : 480-90.
PubMed
6) LeRoy EC, Black C, Fleischmajer F, et al. Scleroderma (systemic sclerosis) : classification, subsets and pathogenesis. J Rheumatol 1988 ; 15 : 202-4.
 
7) 竹原和彦. 全身性強皮症の病型分類. 皮膚臨床 1988 ; 30 : 1499-505.
 
P.124 掲載の参考文献
1) American Rheumatism Association. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980 ; 23 : 581-90.
PubMed
2) 竹原和彦, 佐藤伸一, 古江増隆. 全身性強皮症・診療ガイドライン. 日皮会誌 2007 ; 117 : 2431-43.
 
P.131 掲載の参考文献
1) Sato S, Hamaguchi Y, Hasegawa M, et al. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology (Oxford) 2001 ; 40 : 1135-40.
PubMed
2) Hachulla E, Denton CP. Early intervention in pulmonary arterial hypertension associated with systemic sclerosis : an essential component of disease management. Eur Respir Rev 2010 ; 19 : 314-20.
 
3) Hamaguchi Y, Hasegawa M, Fujimoto M, et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 2008 ; 158 : 487-95.
PubMed
4) Kuwana M, Kaburaki J, Okano Y, et al. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994 ; 37 : 75-83.
PubMed
5) Kuwana M, Okano Y, Kaburaki J, et al. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum 1994 ; 37 : 902-6.
PubMed
6) Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005 ; 35 : 35-42.
PubMed
7) 竹原和彦, 佐藤伸一, 古江増隆. 全身性強皮症・診療ガイドライン. 日皮会誌 2007 ; 117 : 2431-43.
 
8) Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006 ; 354 : 2655-66.
PubMed
9) 桑名正隆, 三森経世, 浜信昭, ほか. 全身性強皮症で免疫沈降法により同定される抗核小体抗体の臨床的意義. リウマチ 1992 ; 32 : 39-46.
 
10) Okano Y, Medsger TA Jr. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 1990 ; 33 : 1822-8.
 
11) 小村一浩, Bae SangJae, 小川文秀, ほか. 抗hUBF抗体陽性の全身性強皮症の1例. 日皮会誌 2007 ; 117 : 1621-4.
 
12) 錦織知穂, 平野貴士, 加治賢三, ほか. 経過中に関節リウマチを合併した抗hUBF抗体陽性全身性強皮症. 皮膚臨床 2008 ; 50 : 329-31.
 
P.137 掲載の参考文献
1) Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis : an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993 ; 20 : 1892-6.
PubMed
P.141 掲載の参考文献
1) 藤本学, ほか. 創傷・熱傷ガイドライン : 膠原病・血管炎にともなう皮膚潰瘍診療ガイドライン. (近日中に日皮会誌に掲載予定)
 
1) Harrison BJ, Silman AJ, Hider SL, et al. Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis. Arthritis Rheum 2002 ; 46 : 3312-6.
PubMed
2) Finch MB, Dawson J, Johnston GD. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma : a double blind crossover study. Clin Rheumatol 1986 ; 5 : 493-8.
PubMed
3) Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001 ; 44 : 1841-7.
PubMed
4) 西岡清, 片山一朗, 近藤啓文, ほか. 全身性強皮症に伴うレイノー症状に対する薬物療法の評価. 厚生省特定疾患強皮症調査研究班平成7年度研究報告書. 1996. pp2248-57.
 
5) 佐藤伸一, 室井栄治, 小村一浩, ほか. 全身性強皮症に伴うレイノー症状に対するシロスタゾールの有効性. 臨牀と研究 2007 ; 84 : 984-6.
Medical*Online
6) Gardinali M, Pozzi MR, Bernareggi M, et al. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. J Rheumatol 2001 ; 28 : 786-94.
PubMed
7) Vayssairat M. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. J Rheumatol 1999 ; 26 : 2173-8.
 
8) 清水隆弘, 郷良秀典, 藤田直紀. 足背動脈の閉塞を伴った全身性強皮症 アルガトロバンが有効であった1例. 皮膚臨床 2005 ; 47 : 638-9.
 
9) Korn JH, Mayes M, Matucci-Cerinic M, et al. Digital ulcers in systemic sclerosis : prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004 ; 50 : 3985-93.
PubMed
10) Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis : results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011 ; 70 : 32-8.
PubMed
11) Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005 ; 112 : 2980-5.
PubMed
12) Brueckner CS, Becker MO, Kroencke T, et al. Effect of sildenafil on digital ulcers in systemic sclerosis : analysis from a single centre pilot study. Ann Rheum Dis 2010 ; 69 : 1475-8.
PubMed
P.144 掲載の参考文献
1) 全身性強皮症診療ガイドライン http://web.kanazawa-u.ac.jp/~med24/SSc/pamphret/pdf/guidelines.pdf
 
1) DeMarco PJ, Weisman MH, Seibold JR, et al. Predictors and outcomes of scleroderma renal crisis : the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002 ; 46 : 2983-9.
PubMed
2) Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis : analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999 ; 42 : 1194-203.
PubMed
3) Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006 ; 354 : 2655-66.
PubMed
4) Filaci G, Cutolo M, Scudeletti M, et al. Cyclosporin A and iloprost treatment of systemic sclerosis : clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxford) 1999 ; 38 : 992-6.
PubMed
5) Morton SJ, Powell RJ. Cyclosporin and tacrolimus : their use in a routine clinical setting for scleroderma. Rheumatology (Oxford) 2000 ; 39 : 865-9.
 
6) Sunderkotter C, Kuhn A, Hunzelmann N, et al. Phototherapy : a promising treatment option for skin sclerosis in scleroderma? Rheumatology (Oxford) 2006 ; 45 (Suppl 3) : iii52-4.
 
P.147 掲載の参考文献
1) Hamaguchi Y. Autoantibody profiles in systemic sclerosis : predictive value for clinical evaluation and prognosis. J Dermatol 2010 ; 37 : 42-53.
PubMed
1) Nannini C, West CP, Erwin PJ, et al. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease : a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008 ; 10 : R124.
PubMed
2) Antoniou KM, Margaritopoulos G, Economidou F, et al. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009 ; 33 : 882-96.
PubMed
3) Goldin JG, Lynch DA, Strollo DC, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008 ; 134 : 358-67.
PubMed
4) Goldin J, Elashoff R, Kim HJ, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo : findings from the scleroderma lung study. Chest 2009 ; 136 : 1333-40.
PubMed
5) Hant FN, Ludwicka-Bradley A, Wang HJ, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 2009 ; 36 : 773-80.
PubMed
6) Yanaba K, Hasegawa M, Takehara K, et al. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004 ; 31 : 1112-20.
PubMed
7) Asano Y, Ihn H, Yamane K, et al. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum 2001 ; 44 : 1363-9.
PubMed
8) Takahashi H, Kuroki Y, Tanaka H, et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000 ; 162 : 258-63.
 
9) Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008 ; 177 : 91-8.
PubMed
10) Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis : a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009 ; 68 : 620-8.
 
11) Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006 ; 354 : 2655-66.
PubMed
12) Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006 ; 54 : 3962-70.
PubMed
13) 小川文秀, 佐藤伸一. 皮膚科医による膠原病診断と治療 : 免疫抑制剤および新規治療剤の使い方. MB Derma 2008 ; 136 : 64-9.
 
P.150 掲載の参考文献
1) Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 2003 ; 29 : 315-33.
PubMed
1) 全身性強皮症診療ガイドライン作成委員会. 腎臓病変. 全身性強皮症診療ガイドライン. 東京 : 強皮症調査研究班事務局 ; 2010. pp57-63.
 
2) 全身性強皮症診療ガイドライン作成委員会. 肺高血圧症. 全身性強皮症診療ガイドライン. 東京 : 強皮症調査研究班事務局 ; 2010. pp19-35.
 
2) Endo H, Hosono T, Kondo H. Antineutrophilic cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis. J Rheum 1994 ; 21 : 864-70.
PubMed
3) Simonneau G, Robbins IM, Beghetti M. Update clinical classification of pulmonary hypertension. J Am Coll Cardol 2009 ; 54 : 43-54.
 
4) Barst RJ, Gibbs JSR, Ghofrani HA, et al. Updated evidence-based treatment algolism in pulmonary hypertension. J Am Coll Cardol 2009 ; 54 : 78-84.
 
5) Champion HC. The heart in scleroderma. Rheum Dis Clin North Am 2008 ; 34 : 181-90.
PubMed
P.154 掲載の参考文献
1) 厚生労働省強皮症調査研究班, 編. 全身性強皮症リハビリテーションプログラム. 2010年1月. http://web.kanazawa-u.ac.jp/~med24/SSc/pamphret/pdf/rehabilitation.pdf
 
2) Mugii N, Hasegawa M, Sato S, et al. The Efficacy of self-administered stretching for finger joint motion in Japanese patients with systemic sclerosis. J Rheumatol 2006 ; 33 : 1586-92.
PubMed
3) 麦井直樹, 長谷川稔, 佐藤伸一, ほか. 全身性強皮症の顔に対するリハビリテーション-第2報. 強皮症における病因解明と根治的治療法の開発 平成22年度 総括・分担研究報告書. 2011.
 
P.158 掲載の参考文献
1) LeRoy EC, Black C, Fleischmajer F, et al. Scleroderma (systemic sclerosis) : classification, subsets and pathogenesis. J Rheumatol 1988 ; 15 : 202-4.
 
2) 竹原和彦. 全身性強皮症の病型分類. 皮膚臨床 1988 ; 30 : 1499-505.
 
3) 竹原和彦, 佐藤伸一, 古江増隆, ほか. 全身性強皮症・診療ガイドライン (解説). 日皮会誌 2007 ; 117 : 2431-43.
 
P.161 掲載の参考文献
1) Dieude P, Boileau C, Allanore Y. Immunogenetics of systemic sclerosis. Autoimmun Rev 2011 ; 10 : 282-90.
PubMed
1) Arnett FC, Cho M, Chatterjee S, et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001 ; 44 : 1359-62.
PubMed
2) 土屋尚之, 伊東郁恵, 川崎 綾. IRF5, STAT4, BLKと全身性エリテマトーデスをはじめとする膠原病との関連. 日本臨床免疫学会会誌 2010 ; 33 : 57-65.
Medical*Online
2) Radstake TR, Gorlova O, Rueda B, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010 ; 42 : 426-9.
PubMed
3) Kuwana M, Kaburaki J, Arnett FC, et al. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999 ; 42 : 465-74.
PubMed
4) Kuwana M, Inoko H, Kameda H, et al. Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis. Intern Med 1999 ; 38 : 336-44.
 
5) Arnett FC, Gourh P, Shete S, et al. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis : analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis 2010 ; 69 : 822-7.
PubMed
6) Ito I, Kawaguchi Y, Kawasaki A, et al. Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum 2009 ; 60 : 1845-50.
 
7) Dieude P, Guedj M, Wipff J, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis : a new perspective for pulmonary fibrosis. Arthritis Rheum 2009 ; 60 : 225-33.
PubMed
8) Tsuchiya N, Kawasaki A, Hasegawa M, et al. Association of STAT4 polymorphism with systemic sclerosis in a Japanese population. Ann Rheum Dis 2009 ; 68 : 1375-6.
 
9) Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009 ; 18 : 2071-7.
PubMed
10) Dieude P, Guedj M, Wipff J, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009 ; 60 : 2472-9.
PubMed
11) Ito I, Kawaguchi Y, Kawasaki A, et al. Association of the FAM167A-BLK region with systemic sclerosis. Arthritis Rheum 2010 ; 62 : 890-5.
PubMed
12) Gourh P, Agarwal SK, Martin E, et al. Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. J Autoimmun 2010 ; 34 : 155-62.
PubMed
13) Diaz-Gallo LM, Gourh P, Broen J, et al. Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Ann Rheum Dis 2011 ; 70 : 454-62.
PubMed
14) Fonseca C, Lindahl GE, Ponticos M, et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007 ; 357 : 1210-20.
PubMed
15) Kawaguchi Y, Ota Y, Kawamoto M, et al. Association study of a polymorphism of the CTGF gene and susceptibility to systemic sclerosis in the Japanese population. Ann Rheum Dis 2009 ; 68 : 1921-4.
PubMed
16) Rueda B, Simeon C, Hesselstrand R, et al. A large multicentre analysis of CTGF-945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype. Ann Rheum Dis 2009 ; 68 : 1618-20.
PubMed
17) Dieude P, Guedj M, Wipff J, et al. Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann Rheum Dis 2010 ; 69 : 1958-64.
PubMed
18) Dieude P, Guedj M, Truchetet ME, et al. Association of the CD226 Ser (307) variant with systemic sclerosis : evidence for a contribution of co-stimulation pathways in SSc pathogenesis. Arthritis Rheum 2011 ; 63 : 1097-105.
 
19) Gourh P, Arnett FC, Tan FK, et al. Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann Rheum Dis 2010 ; 69 : 550-5.
PubMed
20) Rueda B, Gourh P, Broen J, et al. BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. Ann Rheum Dis 2010 ; 69 : 700-5.
PubMed
P.166 掲載の参考文献
1) Sato S, Fujimoto M, Hasegawa M, et al. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004 ; 41 : 1123-33.
PubMed
2) Hasegawa M, Hamaguchi Y, Yanaba K, et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006 ; 169 : 954-66.
PubMed
3) Smith V, Van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis : an open label clinical and histopathological study. Ann Rheum Dis 2008 ; 69 : 193-97.
 
4) Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009 ; 60 : 578-83.
PubMed
5) Daoussis D, Stamatis-Nick C, Athanassios C, et al. Experience with rituximab in scleroderma : results from a 1-year, proof-of-principle study. Rheumatology 2010 ; 49 : 271-80.
 
6) Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis : safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010 ; 12 : R54.
 
P.169 掲載の参考文献
1) Bournia VK, Vlachoyiannopoulos PG, Selmi C, et al. Recent advances in the treatment of systemic sclerosis. Clin Rev Allergy Immunol 2009 ; 36 : 176-200.
PubMed
1) Galluccio F, Walker UA, Nihtyanova S, et al. Registries in systemic sclerosis : a worldwide experience. Rheumatology (Oxford) 2010 ; 50 : 60-8.
 
2) Pannu J, Asano Y, Nakerakanti S, et al. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 2008 ; 58 : 2528-37.
PubMed
3) Radstake TR, van Bon L, Broen J, et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 2009 ; 4 : e5903.
PubMed
4) Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001 ; 344 : 1038-42.
PubMed
5) Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002 ; 347 : 472-80.
PubMed
6) Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007 ; 56 : 311-22.
PubMed
7) Soria A, Cario-Andre M, Lepreux S, et al. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts : a preclinical study. Dermatology 2008 ; 216 : 109-17.
PubMed
8) Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005 ; 353 : 1412-3.
PubMed
9) van Daele PL, Dik WA, Thio HB, et al. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 2008 ; 58 : 2549-52.
PubMed
10) Sabnani I, Zucker MJ, Rosenstein ED, et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications : safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford) 2009 ; 48 : 49-52.
 
11) Nagai S, Hamada K, Shigematsu M, et al. Open-label compassionate use one yeartreatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002 ; 41 : 1118-23.
PubMed
12) Bhatt N, Baran CP, Allen J, et al. Promising pharmacologic innovations in treating pulmonary fibrosis. Curr Opin Pharmacol 2006 ; 6 : 284-92.
PubMed
13) Yoshizaki A, Yanaba K, Iwata Y, et al. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum 2010 ; 62 : 2476-87.
PubMed
14) Su TI, Khanna D, Furst DE, et al. Rapamycin versus methotrexate in early diffuse systemic sclerosis : results from a randomized, single-blind pilot study. Arthritis Rheum 2009 ; 60 : 3821-30.
PubMed
15) Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010 ; 49 : 2408-12.
PubMed
P.172 掲載の参考文献
1) Maurer B, Busch N, Jungel A, et al. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation 2009 ; 120 : 2367-76.
PubMed
1) Yamamoto T. Animal model of systemic sclerosis. J Dermatol 2010 ; 37 : 26-41.
PubMed
2) Asano Y, Stawski L, Hant F, et al. Endothelial Fli1 deficiency impairs vascular homeostasis : a role in scleroderma vasculopathy. Am J Pathol 2010 ; 176 : 1983-98.
PubMed
2) Mountz JD, Downs Minor MB, Turner R, et al. Bleomycin-induced cutaneous toxicity in the rat : analysis of histopathology and ultrastructure compared with progressive systemic sclerosis (scleroderma). Br J Dermatol 1983 ; 108 : 679-86.
PubMed
3) Asano Y, Markiewicz M, Kubo M, et al. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol 2009 ; 29 : 425-34.
PubMed
3) Yamamoto T, Takagawa S, Katayama I, et al. Animal model of sclerotic skin. I : Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999 ; 112 : 456-62.
PubMed
4) Shinozaki M, Kawara S, Hayashi N, et al. Induction of subcutaneous tissue fibrosis in newborn mice by transforming growth factor beta-simultaneous application with basic fibroblast growth factor causes persistent fibrosis. Biochem Biophys Res Commun 1997 ; 240 : 292-7.
PubMed
5) Mori T, Kawara S, Shinozaki M, et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis : a mouse fibrosis model. J Cell Physiol 1999 ; 181 : 153-9.
 
6) Green MC, Sweet HO, Bunker LE. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976 ; 82 : 493-512.
PubMed
7) Kasturi KN, Shibata S, Muryoi T, et al. Tight-skin mouse an experimental model for scleroderma. Int Rev Immunol 1994 ; 11 : 253-71.
PubMed

VIII 限局性強皮症

P.176 掲載の参考文献
1) Fox TC. Note on the history of scleroderma in England. Br J Dermatol 1982 ; 4 : 101-4.
 
2) Tuffanelli DL, Winkelmann RK. Systemic scleroderma : a clinical study of 727 cases. Arch Dermatol 1961 ; 84 : 359-71.
PubMed
3) Saxton-Daniels S, Jacob HT. An evaluation of long-term outcomes in adults with pediatric onset morphea. Arch Dermatol 2010 ; 146 : 1044-5.
 
4) 大澤一弘, 秋元幸子, 石川治, ほか. 群馬大学皮膚科における限局性強皮症の臨床的検討. 日皮会誌 1997 ; 107 : 1479-83.
 
5) 水谷仁. 強皮症と鑑別を要する皮膚硬化. 皮膚病診療 1996 ; 18 : 679-83.
 
P.179 掲載の参考文献
1) Tuffanelli DL, Winkelmann RK. Systemic scleroderma : a clinical study of 727 cases. Arch Dermatol 1961 ; 84 : 359-71.
PubMed
2) Soma Y, Fujimoto M. Frontoparietal scleroderma (en coup de sabre) following Blaschko's lines. J Am Acad Dermatol 1998 ; 38 : 366-8.
 
3) Soma Y, Kawakami T, Yamasaki E, et al. Linear scleroderma along Blaschko's lines in a patient with systematized morphea. Acta Derm Venereol 2003 ; 83 : 362-4.
 
4) Sommer A, Gambichler T, Bacharach-Buhles M, et al. Clinical and serological characteristics of progressive facial hemiatrophy : a case series of 12 patients. J Am Acad Dermatol 2006 ; 54 : 227-233.
PubMed
5) 佐藤伸一. 限局性強皮症の診断と治療. 皮膚臨床 2010 ; 52 : 1047-56.
 
P.182 掲載の参考文献
1) Sato S, Ihn H, Soma Y, et al. Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum 1993 ; 36 : 1137-41.
PubMed
2) Sato S, Fujimoto M, Ihn H, et al. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J Am Acad Dermatol 1994 ; 31 : 567-71.
PubMed
3) 竹原和彦, 尹浩信, 佐藤伸一, ほか. 限局性強皮症における抗1本鎖DNA抗体-抗体価の推移が治療上の参考となった2例. 皮膚臨床 1993 ; 35 : 737-40.
 
4) Hasegawa M, Fujimoto M, Hayakawa I, et al. Anti-phosphatidylserine-prothrombin complex antibodies in patients with localized scleroderma. Clin Exp Rheumatol 2006 ; 24 : 19-24.
 
5) Sato S, Fujimoto M, Hasegawa M, et al. Antiphospholipid antibody in localised scleroderma. Ann Rheum Dis 2003 ; 62 : 771-4.
PubMed
6) 藤本学, 佐藤伸一, 尹浩信, ほか. 限局性強皮症における抗heat-shock protein90抗体. 日皮会誌 1994 ; 104 : 1025-8.
 
7) el-Azhary RA, Aponte CC, Nelson AM. Do antihistone autoantibodies reflect disease activity in linear scleroderma? Arch Dermatol 2004 ; 140 : 759-60.
PubMed
8) Sato S, Fujimoto M, Ihn H, et al. Antigen specificity of antihistone antibodies in localized scleroderma. Arch Dermatol 1994 ; 130 : 1273-7.
PubMed
9) Matsushita T, Hasegawa M, Matsushita Y, et al. Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol 2007 ; 16 : 87-93.
PubMed
P.185 掲載の参考文献
1) Falanga V, Meddger TA Jr, Reichlin M, et al. Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med 1986 ; 104 : 849-57.
 
2) Takehara K, Moroi Y, Nakabayashi Y, et al. Antinuclear antibodies in localized scleroderma. Arthritis Rheum 1983 ; 26 : 612-6.
PubMed
3) Sato S, Ihn H, Soma Y, et al. Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum 1993 ; 36 : 1137-41.
PubMed
4) Takehara K, Kikuchi K, Soma Y, et al. Anti-single-stranded DNA antibody and muscle involvement in localized scleroderma. Arch Dermatol 1990 ; 126 : 1368.
PubMed
5) Mimura Y, Ihn H, Jinnin M, et al. Rheumatoid factor isotypes in localized scleroderma. Clin Exp Dermatol 2005 ; 30 : 405-8.
PubMed
6) Fujimoto M, Sato S, Ihn H, et al. Autoantibodies to mitochondrial 2-oxo-acid dehydrogenase complexes in localized scleroderma. Clin Exp Immunol 1996 ; 105 : 297-301.
PubMed
7) Yamane K, Ihn H, Kubo M, et al. Anti-U1RNP antibodies in patients with localized scieroderma. Arch Dermatol Res 2001 ; 293 : 455-9.
PubMed
8) Mimura Y, Ihn H, Jinnin M, et al. Anti-agalactosyl immunoglobulin G antibodies in localized scleroderma. Int J Dermatol 2005 ; 44 : 817-20.
 
9) Sato S, Fujimoto M, Hasegawa M, et al. Antiphospholipid antibody in localised scleroderma. Ann Rheum Dis 2003 ; 62 : 771-4.
PubMed
10) Ihn H, Sato S, Fujimoto M, et al. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma. Br J Dermatol 1996 ; 134 : 843-7.
PubMed
11) Jinnin M, Ihn H, Asano Y, et al. A case of linear scleroderma with muscle calcification. Br J Dermatol 2002 ; 146 : 1084-6.
PubMed

IX 強皮症類縁疾患

P.190 掲載の参考文献
1) イイタニ マロト・マリア, 石黒直子, 川島真. 汎発性強皮症に併発した深在性モルフェアの1例. 臨皮 2005 ; 59 : 1183-5.
 
2) Bielsa I, Ariza A. Deep morphea. Semin Cutan Med Surg 2007 ; 26 : 90-5.
PubMed
3) 竹原和彦. 臨床皮膚科-最近のトピックス ステロイド内服療法が適応となる場合強皮症. 臨皮 1995 ; 49 : 150-2.
 
4) Su WP, Person JR. Morphea profunda : a new concept and a histopathologic study of 23 cases. Am J Dermatopathol 1981 ; 3 : 251-60.
 
P.193 掲載の参考文献
1) Mizutani T, Mizutani H, Hashimoto K, et al. Simultaneous development of two cases of eosinophilia-myalgia syndrome with the same lot of L-tryptophan in Japan. J Am Acad Dermatol 1991 ; 25 : 512-7.
PubMed
2) 鈴木亜希子, 磯貝善蔵, 森田明理, ほか. 化学物質の関与が考えられた好酸球性筋膜炎の1例. 中部リウマチ 2004 ; 35 : 168-9.
 
3) Mosconi S, Streit M, Bronimann M, et al. Eosinophilic fasciitis (Shulman syndrome). Dermatology 2002 ; 205 : 204-6.
PubMed
4) Fujimoto M, Sato S, Ihn H, et al. Serum aldolase level is a useful indicator of disease activity in eosinophilic fasciitis. J Rheumatol 1995 ; 22 : 563-5.
PubMed
5) Nakajima H, Fujiwara S, Shinoda K, et al. Magnetic resonance imaging and serum aldolase concentration in eosinophilic fasciitis. Intern Med 1997 ; 36 : 654-6.
PubMed
6) Nindl M, 藤本学, 菊池かな子, ほか. Morpheaを伴った好酸球性筋膜炎の1例. 皮膚臨床 1996 ; 38 : 2013-7.
 
7) Naschitz JE, Yeshurun D, Zuckerman E, et al. Cancer-associated fasciitis panniculitis. Cancer 1994 ; 73 : 231-5.
PubMed
P.197 掲載の参考文献
1) 藤本学. 結節状強皮症. 玉置邦彦, ほか編. 最新皮膚科学大系 9. 膠原病 非感染性肉芽腫. 東京 : 中山書店 ; 2002. pp122-4.
 
2) Micalizzi C, Parodi A, Rebora A. Morphoea with nodular lesions. Br J Dermatol 1994 ; 131 : 298-300.
PubMed
3) Jain K, Dayal S, Jain VK, et al. Blaschko linear nodular morphea with dermal mucinosis. Arch Dermatol 2007 ; 143 : 953-5.
PubMed
4) Melani L, Caproni M, Cardinali C, et al. A case of nodular scleroderma. J Dermatol 2005 ; 32 : 1028-31.
 
5) Barzilai A, Lyakhovitsky A, Horowitz A, et al. Keloid-like scleroderma. Am J Dermatopathol 2003 ; 25 : 327-30.
PubMed
6) Mizutani H, Taniguchi H, Sakakura T, et al. Nodular scleroderma : focally increased tenascin expression differing from that in the surrounding scleroderma skin. J Dermatol 1995 ; 22 : 267-71.
PubMed
7) Yamamoto T, Sawada Y, Katayama I, et al. Nodular scleroderma : increased expression of connective tissue growth factor. Dermatology 2005 ; 211 : 218-23.
PubMed
8) Yamamoto T, Sakashita S, Sawada Y, et al. Possible role of epidermal growth factor in the lesional skin of nodular morphea. Acta Derm Venereol 1998 ; 78 : 312-3.
PubMed
9) Kauer F, Simon JC, Sticherling M. Nodular morphea. Dermatology 2009 ; 218 : 63-6.
PubMed
P.200 掲載の参考文献
1) Sumi K, Yamamoto T, Nishioka K. Amyloid deposition associated with generalized morphea-like scleroderma. Eur J Dermatol 2003 ; 13 : 509-11.
PubMed
2) Kikuchi N, Sakai E, Nishibu A, et al. Primary localized cutaneous amyloidosis associated with systemic sclerosis. Acta Derm Venereol 2010 ; 90 : 326-7.
 
3) Yamamoto T, Furuse Y, Katayama I, et al. Nodular scleroderma in a worker using a silica-containing abrasive. J Dermatol 1994 ; 21 : 751-4.
 
4) Haustein U-F, Herrmann K. Environmental scleroderma. Clin Dermatol 1994 ; 12 : 467-73.
PubMed
5) Bovenzi M, Barbone F, Pisa FE, et al. A case-control study of occupational exposures and systemic sclerosis. Int Arch Occup Environ Health 2004 ; 77 : 10-6.
PubMed
6) Maitre A, Hours M, Bonneterre V, et al. Systemic sclerosis and occupational risk factors : role of solvents and cleaning products. J Rheumatol 2004 ; 31 : 2395-401.
PubMed
7) Gold LS, Ward MH, Dosemeci M, et al. Systemic autoimmune disease mortality and occupational exposures. Arthritis Rheum 2007 ; 56 : 3189-201.
PubMed
8) Mora GF. Systemic sclerosis : environmental factors. J Rheumatol 2009 ; 36 : 2383-96.
PubMed
P.203 掲載の参考文献
1) Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979 ; 22 : 665-7.
 
2) Zimmerman GC, Keeling JH, Burris HA, et al. Taxol (Paclitaxel). [Package insert]. Princeton : Bristol-Myers Squibb ; 1994.
 
3) Bronstad A, Berg A, Reed RK. Effects of taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol 2004 ; 287 : 963-8.
 
4) Battafarano DF, Zimmerman GC, Older SA, et al. Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. Cancer 1995 ; 76 : 110-5.
PubMed
5) 簗場広一, 伊藤宗成, 谷戸克己, ほか. タキサン製剤による強皮症様皮膚硬化. 日皮会誌 2006 ; 116 : 201-7.
 
6) Sato S. Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 1999 ; 11 : 503-7.
PubMed
7) Burkhart CA, Berman JW, Swindell CS, et al. Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxity. Cancer Res 1994 ; 54 : 5779-82.
PubMed
8) Tsavaris N, Kosmas C, Vadiaka M, et al. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002 ; 87 : 21-7.
PubMed
P.206 掲載の参考文献
1) Yamakage A, Ishikawa H. Generalized morphea-like scleroderma occurring in people exposed to organic solvents. Dermatologica 1982 ; 165 : 186-93.
PubMed
2) 田村多絵子, 石川英一. Generalized morphea-like PSS. 臨皮 1989 ; 43 : 586-9.
 
3) 石川治 田村多絵子 樋口忠義, ほか. Generalized morphea-like scleroderma. 皮膚病診療 1996 ; 18 : 729-32.
 
4) Silman JA, Jones S. What is the contribution of occupational environmental factors to the occurrence of scleroderma in man? Ann Rheum Dis 1992 ; 51 : 1322-4.
 
P.209 掲載の参考文献
1) Hallopeau H. Lichen plan et sa forme atrophique. Union Med Can 1887 ; 14 : 729-33.
 
2) Kaya G, Augsburger E, Stamenkovic I, et al. Decrease in epidermal CD44 expression as a potential mechanism for abnormal hyaluronate accumulation in superficial dermis in lichen sclerosus et atrophicus. J Invest Dermatol 2000 ; 115 : 1054-8.
PubMed
3) Marren P, Dean D, Charnock M, et al. The basement membrane zone in lichen sclerosus : an immunohistochemical study. Br J Dermatol 1997 ; 136 : 508-14.
PubMed
4) Oyama N, Chan I, Neill SM, et al. Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet 2003 ; 362 : 118-23.
PubMed
5) Todd P, Halpern S, Kirby J, et al. Lichen sclerosus and the Kobner phenomenon. Clin Exp Dermatol 1994 ; 19 : 262-3.
 
6) Uitto J, Santa Cruz DJ, Bauer EA, et al. Morphea and lichen sclerosus et atrophicus. Clinical and histopathologic studies in patients with combined features. J Am Acad Dermatol 1980 ; 3 : 271-9.
PubMed
7) Dalziel KL, Millard PR, Wojnarowska F. The treatment of vulval lichen sclerosus with a very potent topical steroid (clobetasol propionate 0.05 %) cream. Br J Dermatol 1991 ; 124 : 461-4.
 

X 皮膚筋炎

P.214 掲載の参考文献
1) Olsen NJ, Wortmann RL. Inflammatory and metabolic disease of muscle. In : Wortmann RL, et al. editors. Primer on the Rheumatic Diseases. 11th ed. Atlanta : Arthritis Foundation ; 1997. pp276-82.
 
2) 上阪等. 多発性筋炎・皮膚筋炎の分子標的と制御. 最新医学 2010 ; 39 : 987-91.
 
3) Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975 ; 292 : 344-7.
PubMed
4) Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975 ; 292 : 403-7.
PubMed
5) Tanimoto K, Nakano K, Kano S, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995 ; 22 : 668-74.
PubMed
P.218 掲載の参考文献
1) Tanimoto K, Nakano K, Kano S, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995 ; 22 : 668-74.
PubMed
2) 室慶直. ヘリオトロープ疹の正しい診断. 宮地良樹, 編. 顔の皮膚病最前線. 東京 : メディカルレビュー社 ; 2009. pp120-3.
 
3) 室慶直. 皮膚筋炎の新知見. 玉置邦彦, ほか編. 最新皮膚科学大系 2006-2007. 東京 : 中山書店 ; 2006. pp198-204.
 
P.223 掲載の参考文献
1) Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975 ; 292 : 344-7.
PubMed
2) 木下真男, 高宮清之. 針心電図の実際. 筋電図の読み方. 東京 : 新興医学出版社 ; 1998.
 
3) 埜中征哉. 筋病理組織標本の基礎. 臨床のための筋病理. 東京 : 日本医事新報社 ; 1999.
 
4) 沢田泰之. 皮膚筋炎. MB Derma 2002 ; 63 : 6-15.
 
5) 松下重人, 大桑仁, 清川裕明, ほか. 多発性筋炎, 皮膚筋炎における心病変. Japanese Circulation Journal 1989 ; 53 (suppl 1) : 113.
 
6) 新澤みどり, 真家興隆, 浅沼義博, ほか. 血管病変を基盤とし皮膚の多発潰瘍と消化管穿孔を合併した成人の皮膚筋炎. 日皮会誌 1991 ; 101 : 447-51.
 
7) Bohan A, Peter JB, Bowman RL, et al. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977 ; 56 : 255-86.
PubMed
8) 新井達, 楠舞, 桑原慎治, ほか. 悪性腫瘍を合併した皮膚筋炎の臨床的検討. 日皮会誌 2010 ; 120 : 1196-202.
 
9) Hill CL, Zhang Y, Sigurgerisson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis : a population-based study. Lancet 2001 ; 357 : 96-100.
 
P.229 掲載の参考文献
1) Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002 ; 46 : 626-36.
PubMed
2) Sontheimer RD. Skin manifestations of systemic autoimmune connective tissue disease : diagnostics and therapeutics. Best Pract Res Clin Rheumatol 2004 ; 18 : 429-62.
PubMed
3) Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005 ; 52 : 1571-6.
PubMed
4) Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies : their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 2009 ; 48 : 607-12.
PubMed
5) Betteridge Z, Gunawardena H, North J, et al. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007 ; 56 : 3132-7.
PubMed
6) Ye S, Chen XX, Lu XY, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease : a retrospective cohort study. Clin Rheumatol 2007 ; 26 : 1647-54.
PubMed
7) Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis) : a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006 ; 54 : 597-613.
 
8) Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009 ; 136 : 1341-7.
PubMed
9) Gono T, Kawaguchi Y, Hara M, et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 2010 ; 49 : 1354-60.
PubMed
10) Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007 ; 46 : 124-30.
PubMed
11) Azuma K, Yamada H, Ohkubo M, et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 2011 ; 21 : 178-83.
PubMed
12) Gerami P, Walling HW, Lewis J, et al. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol 2007 ; 157 : 637-44.
 
13) Abe Y, Koyasu Y, Watanabe S, et al. Juvenile amyopathic dermatomyositis complicated by progressive interstitial pneumonia. Pediatr Int 2010 ; 52 : 149-53.
PubMed
P.232 掲載の参考文献
1) Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 1980 ; 23 : 881-8.
PubMed
2) Hashish L, Trieu EP, Sadanandan P, et al. Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with anti-synthetase syndrome. Arthritis Rheum 2005 ; 52 (Suppl 9) : S312.
 
3) Hirakata M, Suwa A, Nagai S, et al. Anti-KS : identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999 ; 162 : 2315-20.
PubMed
4) Targoff IN. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol 1990 ; 144 : 1737-43.
PubMed
5) Bunn CC, Bernstein RM, Mathews MB. Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J Exp Med 1986 ; 163 : 1281-91.
PubMed
6) Mathews MB, Reichlin M, Hughes GR, et al. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med 1984 ; 160 : 420-34.
PubMed
7) Betteridge Z, Gunawardena H, North J, et al. Anti-synthetase syndrome : a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 2007 ; 46 : 1005-8.
PubMed
8) Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy : myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991 ; 70 : 360-74.
 
9) Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006 ; 54 : 3682-9.
PubMed
10) Koreeda Y, Higashimoto I, Yamamoto M, et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med 2010 ; 49 : 361-9.
PubMed
11) Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005 ; 52 : 2439-46.
PubMed
12) Mitra D, Lovell CL, Macleod TI, et al. Clinical and histological features of 'mechanic's hands' in a patient with antibodies to Jo-1 -a case report. Clin Exp Dermatol 1994 ; 19 : 146-8.
 
P.235 掲載の参考文献
1) Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis : an association with malignancy. Rheumatology (Oxford) 2007 ; 46 : 25-8.
PubMed
2) Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006 ; 54 : 3682-9.
PubMed
3) Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007 ; 66 : 1345-9.
PubMed
4) Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008 ; 47 : 324-8.
PubMed
5) Sato S, Kuwana M. Clinically amyopathic dermatomyositis. Curr Opin Rheumatol 2010 ; 22 : 639-43.
PubMed
6) Komura K, Fujimoto M, Matsushita T, et al. Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. J Dermatol Sci 2005 ; 40 : 215-7.
PubMed
P.238 掲載の参考文献
1) Lakhanpal S, Lie JT, Conn DL, et al. Pulmonary disease in polymyositis/dermatomyositis : a clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis 1987 ; 46 : 23-9.
PubMed
2) Takizawa H, Shiga J, Morii Y, et al. Intestitial lung disease in dermatomyositis : clinicopathological study. J Rheumatol 1987 ; 14 : 102-7.
 
3) 曽我隆義, 萩原恵理, 白井輝, ほか. 多発筋炎, 皮膚筋炎に伴う間質性肺病変. 予後不良群について. 厚生省特定疾患びまん性肺疾患調査研究班 平成7年度研究報告書. 1996. pp102-4.
 
4) 立石睦人, 柏崎禎夫, 佐藤篤彦, ほか. PM/DMの間質性肺病変-全国調査. リウマチ科 1997 ; 18 : 125-7.
 
5) 久野英樹, 佐野統. 筋所見に乏しい皮膚筋炎に合併する間質性肺炎に対するカクテル療法の有効性. リウマチ科 2007 ; 37 : 124-8.
 
6) 宮坂信之. 多発性筋炎, 皮膚筋炎に合併した間質性肺炎に対するシクロスポリン療法に関する全国調査. 厚生省特定疾患自己免疫疾患調査研究班 平成11年度研究業績報告書. 2000. pp88-97.
 
7) Tanaka F, Origuchi T, Migita K, et al. Successful combined therapy of cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med 2000 ; 39 : 428-30.
PubMed
8) Ochiai T, Nakajima K, Sakamoto K, et al. Comparative studies on the immunosuppressive activity of FK506, 15-deoxyspergualin, and cyclosporine. Transplant Proc 1989 ; 21 : 829-32.
PubMed
9) Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and intersititial lung disease : a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005 ; 38 : 383-92.
 
10) Yoshimasu T, Otani Y, Sakamoto T, et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002 ; 12 : 50-2.
 
11) Amano H, Nagai Y, Katada K, et al. Successful treatment of cutaneous lesions in juvenile dermatomyositis with high-dose intravenous immunoglobulin. Br J Dermatol 2007 ; 156 : 1390-2.
PubMed

XI Sjogren 症候群

P.246 掲載の参考文献
1) Sjogren H. Zur Kenntnis der Kerato-conjunctivitis Sicca. Acta Opthalmol 1933 ; 11 : 1-151.
 
2) 藤林孝司, 菅井 進, 宮坂信之, ほか. シェーグレン症候群改訂診断基準. 厚生省特定疾患免疫疾患調査研究班平成10年度研究報告書. 1999. pp135-8.
 
3) 若井健志. シェーグレン症候群・成人スティル病の全国疫学調査成績. 厚生省特定疾患難病の疫学調査研究班平成6年度研究業績集. 1995. pp34-40.
 
4) Civilibal M, Canpolat N, Yurt A, et al. A child with primary Sjogren syndrome and a review of the literature. Clin Pediatr (Phila) 2007 ; 46 : 738-42.
 
5) Daniels TE, Fox PC. Salivary and oral components of Sjogren's syndrome. Rheum Dis Clin North Am 1992 ; 18 : 571-89.
PubMed
6) Brookes SM, Cohen SB, Price EJ, et al. T cell clones from a Sjogren's sydrome salivary gland biopsy produce high levels of IL-10. Clin Exp Immunol 1996 ; 103 : 268-72.
 
7) Fox PC, Speight PM. Current concepts of autoimmune exocrinopathy : immunologic mechanisms in the salivary pathology of Sjogren's syndrome. Crit Rev Oral Biol Med 1996 ; 7 : 144-58.
PubMed
P.248 掲載の参考文献
1) Ramirez-Mata M, Pena-Ancira FF, Alarcon-Segovia D. Abnormal esophagal motility in primary Sjogren's syndrome. J Rheumatol 1976 ; 3 : 63-9.
 
2) 中村葉, 横井則彦, 稲富勉, ほか. 原発性および続発性シェーグレン症候群の比較検討. 日眼会誌 2000 ; 104 : 110-3.
 
3) 臼田俊和, 小寺雅也. シェーグレン症候群. MB Derma 2002 ; 63 : 27-35.
 
4) 臼田俊和, 井沢洋平, 安江隆, ほか. 皮疹を主訴としたSjogren症候群. 日皮会誌 1982 ; 92 : 489-501.
 
5) 片山一朗. シェーグレン症候群の皮膚症状. 皮膚臨床 1997 ; 39 : 285-91.
 
6) 菅原京子, 東谷薫, 臼田俊和, ほか. 発熱を伴う皮膚病・Sjogren症候群・SCLEの皮疹を呈した症例. 皮膚病診療 2005 ; 27 : 1441-6.
 
7) 臼田俊和. 環状紅斑 (シェーグレン症候群). 竹原和彦, ほか編. Key word 2000-2001 膠原病. 東京 : 先端医学社 ; 1999. pp30-1.
 
P.254 掲載の参考文献
1) 藤林孝司, 菅井進, 宮坂信之, ほか. シェーグレン症候群改訂診断基準. 厚生省特定疾患免疫疾患調査研究班平成10年度研究報告書. 1999. pp135-8.
 
2) Seror R, Ravaud P, Bowman S, et al. EULAR Sjogren's syndrome disease activity index : development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010 ; 69 : 1103-9.
PubMed
3) 臼田俊和. Sjogren症候群. 玉置邦彦, ほか編. 最新皮膚科学大系 9. 膠原病 非感染性肉芽腫. 東京 : 中山書店 ; 2002. pp142-54.
 
4) Moutsopoulos HM, Zerva LV. Anti-Ro (SS-A) /La (SS-B) antibodies in Sjogren's syndrome. Clin Rheumatol 1990 ; 9 (1 Suppl 1) : 123-30.
 
5) Casals MR, Tzioufas AG, Stone JH, et al. Treatment of primary Sjogren syndrome. JAMA 2010 ; 304 : 452-60.
 
6) Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of Rituximab treatment in primary Sjogren's syndrome. Arthritis Rheum 2010 ; 62 : 960-8.
PubMed

XII 関節リウマチ

P.262 掲載の参考文献
1) Sayah A, English JC 3rd. Rheumatoid arthritis : a review of the cutaneous manifestations. J Am Acad Dermatol 2005 ; 53 : 191-209.
PubMed
1) Sebbag M, Simon M, Vincent C, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995 ; 95 : 2672-9.
PubMed
2) Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000 ; 43 : 155-63.
PubMed
2) Higaki Y, Yamashita H, Sato K, et al. Rheumatoid papules : a report on four patients with histopathologic analysis. J Am Acad Dermatol 1993 ; 28 : 406-11.
PubMed
3) Ichikawa MM, Murata Y, Higaki Y, et al. Rheumatoid neutrophilic dermatitis. Eur J Dermatol 1998 ; 8 : 347-9.
PubMed
3) 宮村知也, 渡邉秀之, 高濱宗一郎, ほか. 早期関節リウマチの診断における抗環状シトルリン化ペプチド抗体 (抗CCP抗体) の有用性の検討. 日臨免会誌 2009 ; 32 : 102-9.
 
4) 三森経世. 自己免疫による関節リウマチの早期診断と臨床経過予測に関する研究-診断未確定関節炎における抗CCP抗体の意義. 厚生労働省免疫アレルギー疾患予防・治療研究事業「関節リウマチの発症及び重篤な合併症の早期診断に関する研究」 (主任研究者江口勝美). 平成16年度研究報告書. 2005. pp25-31.
 
4) Chu P, Connolly MK, LeBoit PE. The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease. Arch Dermatol 1994 ; 130 : 1278-83.
PubMed
5) Sangueza OP, Caudell MD, Mengesha YM, et al. Palisading neutrophilic granulomatous dermatitis in rheumatoid arthritis. J Am Acad Dermatol 2002 ; 47 : 251-7.
PubMed
5) Berglin E, Johansson T, Sundin U, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006 ; 65 : 453-8.
PubMed
6) 龍順之助. 関節リウマチ-外科的治療. 日本リウマチ学会生涯教育委員会・日本リウマチ財団教育研修委員会, 編. リウマチ病学テキスト. 東京 : 診断と治療社 ; 2010. p127.
 

XIII 混合性結合組織病

P.268 掲載の参考文献
1) Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease : an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972 ; 52 : 148-59.
 
2) 衛藤光. MCTD/好酸球性筋膜炎. 日皮会誌 2009 ; 119 : 543-51.
 
3) Jury EC, D'Cruz D, Morrow WJ. Autoantibodies and overlap syndromes in autoimmune rheumatic disease. J Clin Pathol 2001 ; 54 : 340-7.
PubMed
4) 東條毅. 混合性結合組織病の手引き (1996年改訂版). 厚生省特定疾患混合性結合組織病調査研究班 平成9 年度報告書. 1998. pp8-11.
 
5) 近藤啓文. 混合性結合組織病の治療ガイドライン. 厚生労働科学研究難治性疾患克服研究事業混合性結合組織病に関する研究班. 2005. p2.
 
6) 東條毅, 秋吉久美子, 鳥飼勝隆, ほか. 膠原病第4疾患における肺高血圧症の頻度に関する全国調査. 厚生省特定疾患混合性結合組織病調査研究班 平成10年度報告書. 1999. pp3-6.
 
7) 日本循環器学会, ほか. 循環器病の診断と治療に関するガイドライン (2005年度合同研究班報告). 肺高血圧症治療ガイドライン (2006年改訂版). www.j-circ.or.jp/guideline/pdf/JCS2006_nakano_h.pdf
 
8) 西間木友衛, 青塚新一, 国枝武義, ほか. 混合性結合組織病の肺高血圧症診断の手引き. リウマチ 1991 ; 31 : 159-66.
 
9) Hagen NA, Stevens JC, Michet CJ, Jr. Trigeminal sensory neuropathy associated with connective tissue diseases. Neurology 1990 ; 40 : 891-6.
PubMed
10) 鳥飼勝隆, 深谷修作, 国枝武義, ほか. 混合性結合組織病における肺高血圧症の合併率調査. 厚生省特定疾患皮膚・結合織疾患調査研究班混合性結合組織病分科会 平成10年度研究報告書. 1999. pp24-7.
 
11) 吉田俊治, 深谷修作. 膠原病性肺高血圧症の頻度と病態の解析. 厚生労働科学研究費補助金免疫アレルギー疾患予防・治療研究事業 全身性自己免疫疾患における難治性病態の診断と治療法に関する研究 平成15 年度総括・分担研究報告書. 2004. pp40-3.
 

XIV オーバーラップ症候群

P.276 掲載の参考文献
1) Tuffanelli DL. Scleroderma and its relationship to the "collagenoses" : dermatomyositis, lupus erythematosus, rheumatoid arthritis and Sjogren's syndrome. Am J Med Sci 1962 ; 243 : 133-46.
 
2) Jablonska S, Blaszczyk M. Scleroderma overlap syndromes. Adv Exp Med Biol 1999 ; 455 : 85-92.
PubMed
3) 秋月正史. オーバーラップ症候群とMCTD. 日内会誌 1996 ; 85 : 1223-7.
 
4) 菊池かな子. オーバーラップ症候群. MB Derma 2002 ; 63 : 51-4.
 
5) 堤明人. 混合性結合組織病, オーバーラップ症候群. 診断と治療 2006 ; 94 : 1896-900.
Medical*Online
6) 尹浩信. 混合性結合組織病. MB Derma 2002 ; 63 : 37-41.
 
7) Ashida R, Asano Y, Tamaki Z, et al. Close association of anti-U1 ribonucleoprotein antibody with drug allergy in patients with connective tissue diseases. J Dermatol Sci 2010 ; 60 : 56-7.
PubMed

XV 成人Still 病

P.282 掲載の参考文献
1) Bywaters EGL. Still's disease in the adult. Ann Rheum Dis 1971 ; 30 : 121-33.
 
2) 大田明英. 成人Still病 : 最近の知見. 医学のあゆみ 1997 ; 182 : 687-92.
 
3) 芳賀恒夫, 南健, 川上民裕, ほか. 成人Still病 : 皮膚筋炎様の皮疹を呈した症例. 皮膚病診療 2006 ; 28 : 301-4.
 
4) Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992 ; 19 : 424-30.
 
5) 大田明英. 成人Still病. 医学のあゆみ 1998 ; 184 : 945-9.
Medical*Online

XVI ヒトアジュバント病

P.290 掲載の参考文献
1) 熊谷安夫. ヒトアジュバント病の臨床的意義. 臨床免疫 1989 ; 21 : 726-37.
 
2) 三好和夫, 宮岡輝男, 小林泰雄, ほか. 人体におけるAdjuvant加遷延感作を思わせる高γグロブリン血症-乳房形成術の後にみられた障害. 日医新報 1964 ; 2122 : 9-14.
 
3) Kumagai Y, Abe C, Shiokawa Y. Scleroderma after cosmetic surgery : four cases of human adjuvant disease. Arthritis Rheum 1979 ; 22 : 532-7.
PubMed
4) 全峰, 深沢徹, 梁広石, ほか. ヒトアジュバント病に関する臨床的検討. 順天堂医学 2006 ; 52 : 580-7.
 
5) 熊谷安夫. ヒト・adjuvant病. 日内会誌 1991 ; 80 : 1775-8.
 
6) 竹原和彦. 美容外科手術後強皮症. 皮膚臨床 1993 ; 35 : 369-74.
 
7) 藤本学, 佐藤伸一, 竹原和彦, ほか. シリコンロッドを用いた眼科手術後に発症した汎発性強皮症. 皮膚臨床 1994 ; 36 : 43-6.
 

XVII 抗リン脂質抗体症候群

P.294 掲載の参考文献
1) Bowie EJW, Thompson JH, Pascuzzi CA, et al. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963 ; 62 : 416-30.
 
2) Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies : detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983 ; 2 : 1211-4.
PubMed
3) Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986 ; 13 : 486-9.
PubMed
4) Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990 ; 335 : 1544-7.
 
5) Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 ; 4 : 295-306.
 
6) 小林茂人. 抗リン脂質抗体症候群. 疾病対策研究会, 編. 難病の診断と治療指針 2. 三訂版. 東京 : 東京六法出版 ; 2005. pp55-65.
 
7) 渥美達也. 膠原病検査の進歩と診断・治療への応用. 抗リン脂質抗体の特異性と測定意義. 日内会誌 2003 ; 92 : 1948-55.
 
8) Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002 ; 46 : 1019-27.
 
9) Cervera R, Boffa MC, Khamashta MA, et al. The Euro-Phospholipid project : epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009 ; 18 : 889-93.
PubMed
10) 松田重三. 抗リン脂質抗体の産生機序. 抗リン脂質抗体症候群. 東京 : 新興医学出版 ; 2001. pp81-8.
 
11) 渥美達也. 抗リン脂質抗体症候群. 最新医学 2010 ; 65 : 1153-9.
Medical*Online
12) Amengual O, Atsumi T, Khamashta MA, et al. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998 ; 79 : 276-81.
PubMed
P.297 掲載の参考文献
1) Hughes GR. The antiphospholipid syndrome : ten years on. Lancet 1993 ; 342 : 341-4.
PubMed
2) Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 ; 4 : 295-306.
 
3) Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009 ; 7 : 1737-40.
PubMed
4) de Laat B, Mertens K, de Groot PG. Mechanisms of disease : antiphospholipid antibodies-from clinical association to pathologic mechanism. Nat Clin Pract Rheumatol 2008 ; 4 : 192-9.
PubMed
5) Amengual O, Atsumi T, Koike T. Specificities, properties, and clinical significance of antiprothrombin antibodies. Arthritis Rheum 2003 ; 48 : 886-95.
PubMed
6) Sanmarco M. Clinical significance of antiphosphatidylethanolamine antibodies in the so-called "seronegative antiphospholipid syndrome". Autoimmun Rev 2009 ; 9 : 90-2.
PubMed
7) Sweiss NJ, Bo R, Kapadia R, et al. IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. PLoS One 2010 ; 5 : e12280.
PubMed
8) Asherson RA, Cervera R. Microvascular and microangiopathic antiphospholipidassociated syndromes ("MAPS") : semantic or antisemantic? Autoimmun Rev 2008 ; 7 : 164-7.
PubMed
9) Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005 ; 93 : 1147-52.
PubMed
10) Mehdi AA, Uthman I, Khamashta M. Antiphospholipid syndrome : pathogenesis and a window of treatment opportunities in the future. Eur J Clin Invest 2010 ; 40 : 451-64.
 
P.301 掲載の参考文献
1) 秋元智博, 小林茂人, 橋本博史. 抗リン脂質抗体症候群の疫学. リウマチ科 2000 ; 23 : 441-8.
 
2) Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002 ; 46 : 1019-27.
 
3) Gibson GE, Su WP, Pittelkow MR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol 1997 ; 36 : 970-82.
PubMed
4) 片山一朗, 濱崎洋一郎, 有馬優子, ほか. 抗リン脂質抗体症候群. 玉置邦彦, ほか編. 最新皮膚科学大系 9. 膠原病 非感染性肉芽腫. 東京 : 中山書店 ; 2002. pp177-84.
 
5) 内山真一郎, 赫洋美. 膠原病・類縁疾患に伴う神経・筋障害の診断と治療. 抗リン脂質抗体症候群. 日内会誌 2010 ; 99 : 1759-63.
 
6) 渥美達也. 新しい検査の意義と使い方. 抗リン脂質抗体. 日内会誌 2007 ; 96 : 2138-43.
 
7) Godeau B, Piette JC, Fromont P, et al. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol 1997 ; 98 : 873-9.
PubMed
8) Sneddon IB. Cerebro-vascular lesions and livedo reticularis. Br J Dermatol 1965 ; 77 : 180-5.
PubMed
9) Kalashnikova LA, Nasonov EL, Kushekbaeva AE, et al. Anticardiolipin antibodies in Sneddon's syndrome. Neurology 1990 ; 40 : 464-7.
PubMed
10) Kalashnikova LA, Korczyn AD, Shavit S, et al. Antibodies to prothrombin in patients with Sneddon's syndrome. Neurology 1999 ; 53 : 223-5.
PubMed
P.304 掲載の参考文献
1) Hughes GR. The antiphospholipid syndrome : ten years on. Lancet 1993 ; 342 : 341-4.
PubMed
2) Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 ; 4 : 295-306.
 
3) Alegre VA, Gastineau DA, Winkelmann RK. Skin lesion associated with circulating lupus anticoagulant. Br J Dermatol 1989 ; 120 : 419-29.
PubMed
4) Papi M, Didona B, De Pita O, et al. Livedo vasculopathy vs small vessel cutaneous vasculitis : cytokine and platelet P-selectin studies. Arch Dermatol 1998 ; 134 : 447-52.
PubMed
5) Acland KM, Darvay A, Wakelin SH, et al. Livedoid vasculitis : a manifestation of the antiphospholipid syndrome? Br J Dermatol 1999 ; 140 : 131-5.
PubMed
6) Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992 ; 19 : 508-12.
 
7) Pierangeli SS, Erkan D. Antiphospholipid syndrome treatment beyond anticoagulation : are we there yet? Lupus 2010 ; 19 : 475-85.
 
8) Mehdi AA, Uthman I, Khamashta M. Antiphospholipid syndrome : pathogenesis and a window of treatment opportunities in the future. Eur J Clin Invest 2010 ; 40 : 451-64.
 
P.308 掲載の参考文献
1) Hughes GR. The antiphospholipid syndrome : ten years on. Lancet 1993 ; 342 : 341-4.
PubMed
2) Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992 ; 19 : 508-12.
 
3) Bucciarelli S, Cervera R, Espinosa G, et al. Mortality in the catastrophic antiphospholipid syndrome : causes of death and prognostic factors. Autoimmune Rev 2006 ; 6 : 72-5.
PubMed
4) 田村直人. 抗リン脂質抗体症候群の臨床症状と治療 (内科). BIO Clinica 2009 ; 24 : 525-9.
 
5) Espinosa G, Cervera R. Antiphospholipid syndrome. Arthritis Res Ther 2008 ; 10 : 230.
PubMed
6) Erkan D, Asherson RA, Espinosa G, et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 2006 ; 62 : 530-3.
 
7) Bucciarelli S, Erkan D, Espinosa G, et al. Catastrophic antiphospholipid syndrome : treatment, prognosis, and the risk of relapse. Clin Rev Allergy Immunol 2009 ; 36 : 80-4.
PubMed

XVIII Behcet 病

P.312 掲載の参考文献
1) Davatchi F, Shahram F, Chams-Davatchi C, et al. Behcet's disease : from east to west. Clin Rheumatol 2010 ; 29 : 823-33.
PubMed
2) 金子史男. Behcet病. 皮膚臨床 2004 ; 46 : 1416-23.
 
3) de Menthon M, LaValley MP, Maldini C, et al. HLA-B51/B5 and the risk of Behcet's disease : a systematic review and meta-analysis of case-control genetic association studies. Arthtiris Rheum 2009 ; 61 : 1287-96.
 
4) Mizuki N, Ota M, Kimura M, et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene : a strong association of six GCT repetitions with Behcet disease. Proc Natl Acad Sci U S A 1997 ; 94 : 1298-303.
PubMed
5) Mizuki N, Ota M, Katsuyama Y, et al. Association analysis between the MIC-A and HLA-B alleles in Japanese patients with Behcet's disease. Arthritis Rheum 1999 ; 42 : 1961-6.
 
6) Hirohata S, Kikuchi H. Behcet's disease. Arthritis Res Ther 2003 ; 5 : 139-46.
PubMed
7) Kaneko F, Oyama N, Yanagihori H, et al. The role of streptococcal hypersensitivity in the pathogenesis of Behcet's disease. Eur J Dermatol 2008 ; 18 : 489-98.
PubMed
P.315 掲載の参考文献
1) 溝口昌子. Behcet病. 玉置邦彦, ほか編. 最新皮膚科学大系 9. 膠原病 非感染性肉芽腫. 東京 : 中山書店 ; 2002. pp221-32.
 
P.319 掲載の参考文献
1) 溝口昌子. Behcet病. 玉置邦彦, ほか編. 最新皮膚科学大系 9. 膠原病 非感染性肉芽腫. 東京 : 中山書店 ; 2002. pp221-32.
 
2) 菊地弘敏. 腸管Behcet病の臨床. 医学のあゆみ 2005 ; 215 : 73-6.
Medical*Online
3) 広畑俊成. 神経Behcet病の臨床. 医学のあゆみ 2005 ; 215 : 61-6.
Medical*Online
4) Houman MH, Ben Ghorbel I, Khiari Ben Salah I, et al. Deep vein thrombosis in Behcet's disease. Clin Exp Rheumatol 2001 ; 19 (Suppl 24) : S48-50.
 
5) 新見正則. 血管Behcet病の臨床. 医学のあゆみ 2005 ; 215 : 83-7.
Medical*Online
P.322 掲載の参考文献
1) The International Study Group for Behcet's disease. Evaluation of diagnostic ('classification') criteria in Behcet's disease-towards internationally agreed criteria. Br J Rheumatol 1992 ; 31 : 299-308.
 
2) 川上民裕. Sweet病. 宮地良樹, ほか編. 皮膚疾患診療実践ガイド. 東京 : 文光堂 ; 2009. pp330-3.
 
3) 川上民裕. Behcet病・Weber-Christian症候群. 宮地良樹, ほか編. 皮膚疾患診療実践ガイド. 東京 : 文光堂 ; 2009. pp408-13.
 

XIX 血球貪食症候群

P.328 掲載の参考文献
1) Ishii E, Ohga S, Imashuku S, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 2007 ; 86 : 58-65.
PubMed
2) Henter JI, Horne A, Arico M, et al. HLH-2004 : diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007 ; 48 : 124-31.
PubMed
3) Kumakura S, Ishikura H, Kondo M, et al. Autoimmune-associated hemophagocytic syndrome. Mod Rheumatol 2004 ; 14 : 205-15.
PubMed
4) 熊倉俊一. 膠原病に伴う血球貪食症候群 : 治療と予後. 血液・腫瘍科 2008 ; 57 (Suppl 6) : 149-56.
 

XX 膠原病の新規治療

P.334 掲載の参考文献
1) Kraetsch HG, Antoni C, Kalden JR, et al. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab : first experiences. Ann Rheum Dis 2001 ; 60 (Suppl 3) : iii55-7.
 
2) Cavagna L, Caporali R, Epis O, et al. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol 2001 ; 19 : 329-32.
 
3) Kokkinos A, Iliopoulos A, Greka P, et al. Successful treatment of refractory adultonset Still's disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol 2004 ; 23 : 45-9.
PubMed
4) Fautrel B, Sibilia J, Mariette X, et al. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease : an observational study of 20 cases. Ann Rheum Dis 2005 ; 64 : 262-6.
PubMed
5) Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002 ; 46 : 1171-6.
PubMed
6) Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004 ; 31 : 1362-8.
PubMed
7) Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease. Inflamm Bowel Dis 2008 ; 14 : 1259-64.
PubMed
8) Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of neuro-Behcet's disease : a case series and review of the literature. Arthritis Rheum 2008 ; 59 : 285-90.
PubMed
9) Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Behcet's syndrome. J Neurol Sci 2008 ; 272 : 99-105.
PubMed
10) Molloy ES, Langford CA, Clark TM, et al. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis : long-term follow-up. Ann Rheum Dis 2008 ; 67 : 1567-9.
PubMed
11) Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis : a randomized trial. Ann Intern Med 2007 ; 146 : 621-30.
PubMed
12) Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002 ; 41 : 1303-7.
PubMed
13) Booth AD, Jefferson HJ, Ayliffe W, et al. Safety and efficacy of TNF alpha blockade in relapsing vasculitis. Ann Rheum Dis 2002 ; 61 : 559.
PubMed
14) Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005 ; 352 : 351-61.
 
15) Denton CP, Engelhart M, Tvede N, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2009 ; 68 : 1433-9.
PubMed
16) Hengstman GJ, van den Hoogen FH, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha : preliminary observations. Eur Neurol 2003 ; 50 : 10-5.
PubMed
17) Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis : a retrospective study of eight patients. Ann Rheum Dis 2006 ; 65 : 1233-6.
PubMed
P.338 掲載の参考文献
1) Silver JS, Hunter CA. gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol 2010 ; 88 : 1145-56.
 
1) Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986 ; 324 : 73-6.
PubMed
2) Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T (H) 17 lineage. Nature 2006 ; 441 : 231-4.
 
3) Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004 ; 113 : 1271-6.
 
4) Nishimoto N. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther 2010 ; 87 : 483-7.
PubMed
5) Jones SA, Richards PJ, Scheller J, et al. IL-6 transsignaling : the in vivo consequences. J Interferon Cytokine Res 2005 ; 25 : 241-53.
PubMed
6) Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005 ; 5 : 1731-40.
 
7) Ohsugi Y. Recent advances in immunopathophysiology of interleukin-6 : an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull 2007 ; 30 : 2001-6.
PubMed
8) Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis : a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008 ; 371 : 998-1006.
PubMed
9) Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. Lancet 2008 ; 371 : 987-97.
PubMed
10) Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus : data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010 ; 62 : 542-52.
PubMed
11) Nishimoto N. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan. Clin Rev Allergy Immunol 2005 ; 28 : 221-30.
PubMed
12) Matsumoto K, Nagashima T, Takatori S, et al. Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab. Clin Rheumatol 2009 ; 28 : 485-7.
PubMed
13) Nishimoto N, Nakahara H, Yoshio-Hoshino N, et al. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008 ; 58 : 1197-200.
PubMed
14) Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010 ; 49 : 2408-12.
PubMed
15) Yoshimura T, Sonoda KH, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford) 2009 ; 48 : 347-54.
PubMed
16) Serada S, Fujimoto M, Mihara M, et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2008 ; 105 : 9041-6.
PubMed
P.341 掲載の参考文献
1) Sharpe AH, Abbas AK. T-cell costimulation-biology, therapeutic potential, and challenges. N Engl J Med 2006 ; 355 : 973-5.
PubMed
1) Janeway CA, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994 ; 76 : 275-85.
PubMed
2) Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation : challenges and new developments. Immunol Rev 2009 ; 229 : 271-93.
 
3) Maier LM, Hafler DA. Autoimmunity risk alleles in costimulation pathways. Immunol Rev 2009 ; 229 : 322-36.
PubMed
4) Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003 ; 349 : 1907-15.
PubMed
5) Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003 ; 48 : 719-27.
 
6) Kuwana M, Nomura S, Fujimura K, et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004 ; 103 : 1229-36.
PubMed
P.344 掲載の参考文献
1) Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases : an updated perspective. Immunol Rev 2010 ; 237 : 264-83.
PubMed
2) Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004 ; 199 : 1659-69.
PubMed
3) Haas KM, Sen S, Sanford IG, et al. CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J Immunol 2006 ; 177 : 3063-73.
PubMed
4) Uchida J, Lee Y, Hasegawa M, et al. Mouse CD20 expression and function. Int Immunol 2004 ; 16 : 119-29.
PubMed
5) Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura : results of a prospective multicenter phase 2 study. Blood 2008 ; 112 : 999-1004.
PubMed
6) Roccatello D, Baldovino S, Rossi D, et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 2008 ; 34 : 111-7.
PubMed
7) Stieglbauer K, Topakian R, Schaffer V, et al. Rituximab for myasthenia gravis : three case reports and review of the literature. J Neurol Sci 2009 ; 280 : 120-2.
PubMed
8) Erre GL, Pardini S, Faedda R, et al. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome : a case report and a review of literature. Lupus 2008 ; 17 : 50-5.
 
9) Hinze CH, Colbert RA. B-cell depletion in Wegener's granulomatosis. Clin Rev Allergy Immunol 2008 ; 34 : 372-9.
PubMed
10) Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice : 10-year single-institution experience of 142 consecutive patients. Blood 2011 ; 117 : 45-52.
PubMed
11) Sato S, Miller AS, Inaoki M, et al. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction : altered signaling in CD22-deficient mice. Immunity 1996 ; 5 : 551-62.
PubMed
12) Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther 2006 ; 6 : 1341-53.
PubMed
13) Looney RJ. B cell-targeted therapies for systemic lupus erythematosus : an update on clinical trial data. Drugs 2010 ; 70 : 529-40.
PubMed
14) Mackay F, Figgett WA, Saulep D, et al. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev 2010 ; 237 : 205-25.
 
15) Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009 ; 39 : 788-97.
PubMed
16) Simon D, Hosli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008 ; 121 : 122-8.
PubMed
17) Sheinkopf LE, Rafi AW, Do LT, et al. Efficacy of omalizumab in the treatment of atopic dermatitis : a pilot study. Allergy Asthma Proc 2008 ; 29 : 530-7.
PubMed
18) Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007 ; 120 : 1223-5.
 
19) Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009 ; 1173 : 683-91.
PubMed
20) Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009 ; 113 : 3147-53.
PubMed
21) Freim Wahl SG, Folvik MR, Torp SH. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab : case report and review of the literature. Clin Neuropathol 2007 ; 26 : 68-73.
 
P.348 掲載の参考文献
1) Zhang L, Bertucci AM, Ramsey-Goldman R, et al. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation and TGF-β producing CD8+ Treg cells (CD8TGF-β Treg) are associated with immunologic remission of lupus. J Immunol 2009 ; 183 : 6346-58.
 
1) Schachna L, Ryan PF, Schwarer AP. Malignancy-associated remission of systemic lupus erythematosus maintained by autologous peripheral blood stem cell transplantation. Arthritis Rheum 1998 ; 41 : 2271-2.
PubMed
2) Meloni G, Capria S, Vignetti M, et al. Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus : regression of both diseases after autologous bone marrow transplantation. Blood 1997 ; 89 : 4659.
PubMed
3) Openshaw H, Nash RA, McSweeney PA. High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease : clinical review. Biol Blood Marrow Transplant 2002 ; 8 : 233-48.
PubMed
4) Tyndall A, Passweg J, Gratwohl A. Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann Rheum Dis 2001 ; 60 : 702-7.
PubMed
5) Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in autoimmune disease. A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Br J Rheumatol 1997 ; 36 : 390-2.
 
6) Leung Y, Geddes M, Storek J, et al. Hematopoietic cell transplantation for Crohn's disease ; is it time? World J Gastroenterol 2006 ; 12 : 6665-73.
PubMed
7) Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases : an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010 ; 95 : 284-92.
 
8) Farge D, Passweg J, van Laar JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis : report from the EBMT/EULAR Registry. Ann Rheum Dis 2004 ; 63 : 974-81.
PubMed
9) Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004 ; 13 : 168-76.
PubMed
10) Snowden JA, Passweg J, Moore JJ, et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis : a report from the EBMT and ABMTR. J Rheumatol 2004 ; 31 : 482-8.
PubMed
P.351 掲載の参考文献
1) Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002 ; 2 : 580-92.
PubMed
1) Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981 ; 1 : 1228-31.
PubMed
2) Dalakas MC. Sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006 ; 2 : 437-47.
PubMed
3) Xu C, Poirier B, Duong Van Huyen JP, et al. Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins : a possible mechanism of action in vascular diseases. Am J Pathol 1998 ; 153 : 1257-66.
PubMed
4) Prasad NK, Papoff G, Zeuner A, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes : a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998 ; 161 : 3781-90.
PubMed
5) Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001 ; 291 : 484-6.
PubMed
6) Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993 ; 329 : 1993-2000.
PubMed
7) Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis : an open study with thirty-five adult patients. Arthritis Rheum 2002 ; 46 : 467-74.
PubMed
8) Corvetta A, Della Bitta R, Gabrielli A, et al. Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus : report of three cases. Clin Exp Rheumatol 1989 ; 7 : 295-9.
PubMed
9) Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin-clinical and serologic response. Lupus 1999 ; 8 : 705-12.
 
10) Ihn H, Mimura Y, Yazawa N, et al. High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol 2007 ; 156 : 1058-60.
PubMed
11) Levy Y, Amital H, Langevitz P, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis : an open-label study. Arthritis Rheum 2004 ; 50 : 1005-7.
PubMed
12) Asano Y, Ihn H, Asashima N, et al. A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology (Oxford) 2005 ; 44 : 824-6.
PubMed
13) Galeotti C, Bayry J, Kone-Paut I, et al. Kawasaki disease : aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev 2010 ; 9 : 441-8.
PubMed
14) Machet L, Vincent O, Machet MC, et al. Cutaneous periarteritis nodosa resistant to combined corticosteroids and immunosuppressive agents. Efficacy of treatment with intravenous immunoglobulins. Ann Dermatol Venereol 1995 ; 122 : 769-72.
PubMed
15) Richter C, Schnabel A, Csernok E, et al. Treatment of anti-neutrophil cytoplasmic antibody (ANCA) -associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995 ; 101 : 2-7.
PubMed
16) Enk A. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol 2009 ; 19 : 90-8.
 

書評

最近チェックした商品履歴

Loading...